


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:36Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406469" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406469</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>infagcan</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Agent Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Infect Agent Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">439</journal-id><journal-id journal-id-type="pmc-domain">infagcan</journal-id><journal-title-group><journal-title>Infectious Agents and Cancer</journal-title></journal-title-group><issn pub-type="epub">1750-9378</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406469</article-id><article-id pub-id-type="pmcid-ver">PMC12406469.1</article-id><article-id pub-id-type="pmcaid">12406469</article-id><article-id pub-id-type="pmcaiid">12406469</article-id><article-id pub-id-type="pmid">40898263</article-id><article-id pub-id-type="doi">10.1186/s13027-025-00693-9</article-id><article-id pub-id-type="publisher-id">693</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Genetic and transcriptional insights reveal hepatitis C virus as a driver of kidney cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Q">Qiankun</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="T">Tongxin</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feng</surname><given-names initials="Y">Yuting</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ren</surname><given-names initials="H">Huihao</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiao</surname><given-names initials="X">Xiao</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="J">Jiaoyuan</given-names></name><address><email>lijiaoyuan@tjh.tjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Cheng</surname><given-names initials="L">Liming</given-names></name><address><email>chengliming2015@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p991c53</institution-id><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution>Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, </institution><institution>Huazhong University of Science and Technology, </institution></institution-wrap>Wuhan, 430030 P. R. China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue-id pub-id-type="pmc-issue-id">479098</issue-id><elocation-id>63</elocation-id><history><date date-type="received"><day>31</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="13027_2025_Article_693.pdf"/><abstract id="Abs1"><sec><title>Objectives</title><p id="Par1">Observational studies suggest a potential link between Hepatitis C virus (HCV) infection and extrahepatic cancers, but the causal relationship remains unclear.</p></sec><sec><title>Methods</title><p id="Par2">We applied a two-sample Mendelian randomization (MR) approach to evaluate the causal relationships between HCV infection and various extrahepatic cancers. A two-step MR was used to identify potential mediators, followed by colocalization analysis to identify HCV-associated susceptibility genes (HSGs). A pan-cancer analysis using TCGA data was conducted, and a prognostic model based on HSGs was developed using least absolute shrinkage and selection operator (LASSO) regression and Cox models. Genetic risk score (GRS) analysis from the UK Biobank validated our findings.</p></sec><sec><title>Results</title><p id="Par3">We identified a causal link between genetic susceptibility to HCV infection and kidney cancer, both in univariable and multivariable MR analyses. The two-step MR identified five mediators in the causal pathway. <italic toggle="yes">IRF5</italic> was highlighted as a key HSG in both the colocalization and pan-cancer analyses. Our prognostic model incorporating three HSGs predicted overall survival (OS) in kidney cancer patients. GRS analysis confirmed the association.</p></sec><sec><title>Conclusions</title><p id="Par4">The present study provides evidence supporting a causal link between HCV infection and the development of kidney cancer.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13027-025-00693-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HCV</kwd><kwd>Extrahepatic cancers</kwd><kwd>Mendelian randomization</kwd><kwd>Prognosis</kwd><kwd>Genetic risk score</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81903394</award-id><award-id>82272418</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Jiaoyuan</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Liming</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Hepatitis C virus (HCV) is a single-stranded RNA virus primarily spread through direct percutaneous exposure to blood [<xref ref-type="bibr" rid="CR1">1</xref>]. HCV is capable of producing three structural proteins along with seven non-structural proteins. The structural proteins consist of the core protein and two envelope proteins, E1 and E2, while the non-structural proteins comprise NS2, NS3, NS4A, NS4B, NS5A, NS5B, and P7 [<xref ref-type="bibr" rid="CR2">2</xref>]. The HCV transmission typically occurs via blood transfusions, healthcare-related parenteral procedures, or injecting drug use [<xref ref-type="bibr" rid="CR3">3</xref>]. Over the past thirty years, HCV has emerged as a major global health issue and remains a significant concern. According to the World Health Organization (WHO), approximately fifty million individuals were living with HCV in 2022, with around one million new infections and 221,000 deaths attributed to HCV-related complications [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par6">In recent decades, there has been a significant rise in the occurrence of cancer, making it a leading cause of death worldwide. The GLOBOCAN 2020 statistics indicated that there were approximately 19.3&#160;million new cancer cases and around ten million cancer-related fatalities globally [<xref ref-type="bibr" rid="CR5">5</xref>]. HCV has been identified as a carcinogenic agent, notably linked to hepatocellular carcinoma and non-Hodgkin lymphoma [<xref ref-type="bibr" rid="CR6">6</xref>]. However, a growing body of observational studies has suggested a heightened risk of certain extrahepatic cancers among individuals with HCV infection compared to those who are not infected. A retrospective study conducted in the United States between 2008 and 2012 revealed an increased risk of cancers including those of the digestive tract (such as esophageal, gastric, colorectal, and pancreatic cancers), as well as lung, head and neck, kidney, and prostate cancers (PCa) among HCV-infected individuals [<xref ref-type="bibr" rid="CR7">7</xref>]. Moreover, in a recent cross-sectional study from Taiwan, it was observed that chronic HCV infection was associated with elevated incidences of liver, ovarian, and kidney cancers [<xref ref-type="bibr" rid="CR8">8</xref>]. Despite these observations, there is a lack of prospective studies on the association of HCV infection with extrahepatic cancers. Thus, the specific types of extrahepatic cancers linked to HCV and the causal relationships are not fully established and warrant further investigation [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par7">Current hypotheses suggest that HCV may promote the development of extrahepatic cancers. The virus has the capability to infect not only hepatocytes but also extrahepatic cells in organs such as the pancreas, kidneys, and brain [<xref ref-type="bibr" rid="CR10">10</xref>]. This dual infection might lead to carcinogenesis through direct mechanisms, such as persistent inflammation and oncogenic activity in these tissues, or through indirect mechanisms by creating a systemic proinflammatory environment conducive to cancer progression [<xref ref-type="bibr" rid="CR1">1</xref>]. For example, the NS5A protein is known to significantly upregulate cyclooxygenase-2 (COX-2), an enzyme implicated in chronic inflammation and fibrosis via the production of various prostaglandins [<xref ref-type="bibr" rid="CR11">11</xref>]. Moreover, the NS proteins are proved to contribute to the production of proinflammatory chemokines like interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, and regulated upon activation normal T cell expressed and secreted (RANTES), and enhance the expression of intercellular cell adhesion molecule (ICAM)-1, a molecule that promotes T lymphocyte activation [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. These chemokines play critical roles in the recruitment of inflammatory cells to sites of infection. Nevertheless, the exact biological mechanisms linking HCV to extrahepatic cancers remain incompletely understood.</p><p id="Par8">Mendelian randomization (MR) is a statistical methodology that uses single nucleotide polymorphisms (SNPs) as instrumental variables (IVs) to explore causal relationships between exposures and outcomes [<xref ref-type="bibr" rid="CR14">14</xref>]. This approach minimizes the impact of confounding variables, reverse causation, and various biases, as genetic variants are randomly assigned during meiosis, thus operating independently of traditional confounders such as socioeconomic status, environmental exposures, and behavioral factors [<xref ref-type="bibr" rid="CR15">15</xref>]. Until now, there lacks evidence about the causal link between chronic HCV infection and extrahepatic cancers with application of MR analyses. In this study, we implemented both two-sample univariable MR and multivariable MR to assess the causal connections between HCV infection and the incidence of extrahepatic cancers. We also utilized two-step MR to ascertain the potential mediators linking HCV infection to extrahepatic cancers. The genetic risk scores (GRS) analysis was used to further validate our findings. Additionally, we conducted both colocalization and transcriptomic analyses to gain deep insights into the underlying biological mechanisms.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par9">The schematic summary of this study was drawn by Figdraw (<ext-link ext-link-type="uri" xlink:href="https://professional.home-for-researchers.com/#/">https://professional.home-for-researchers.com/#/</ext-link> ) and presented in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par10">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flowchart of the study design</p></caption><graphic id="d33e276" position="float" orientation="portrait" xlink:href="13027_2025_693_Fig1_HTML.jpg"/></fig>
</p><sec id="Sec3"><title>Bidirectional two-sample MR analysis</title><p id="Par11">Within the MR analysis, HCV infection was considered as the exposure factor, with the development of extrahepatic cancer as the outcome of interest. We obtained genome-wide association summary (GWAS) statistics for HCV infection from GWAS Catalog (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/gwas/">https://www.ebi.ac.uk/gwas/</ext-link>). This dataset originated from a 2021 study by Jian Yang et al., which included 219 cases and 456,129 controls of European ancestry from the UK Biobank [<xref ref-type="bibr" rid="CR16">16</xref>]. In order to meet the three basic assumptions of MR, we developed a series of criteria to select the appropriate IVs. Initially, SNPs associated with HCV risk were chosen with a threshold of <italic toggle="yes">P</italic>&#8201;&lt;&#8201;1&#8201;&#215;&#8201;10<sup>&#8722;&#8201;5</sup>, based on prior research [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. We then applied a threshold of r<sup>2</sup>&#8201;=&#8201;0.001 and kb&#8201;=&#8201;10,000 to remove SNPs with linkage disequilibrium. Additionally, we calculated the R<sup>2</sup> and F statistic for each SNP according to the previous studies and excluded SNPs with F&#8201;&lt;&#8201;10. Furthermore, we also used the PhenoScanner database (<ext-link ext-link-type="uri" xlink:href="http://www.phenoscanner.medschl.cam.ac.uk/">http://www.phenoscanner.medschl.cam.ac.uk/</ext-link>) to exclude SNPs directly associated with potential confounders. Through a review of the literature, we included ten cancers potentially associated with HCV infection: brain glioblastoma, lung cancer, esophageal carcinoma, stomach cancer, colorectal cancer, pancreatic cancer, kidney cancer, breast cancer, prostate cancer, and ovarian cancer. The GWAS summary data for these cancers were downloaded from MRC IEU OpenGWAS (<ext-link ext-link-type="uri" xlink:href="https://gwas.mrcieu.ac.uk/">https://gwas.mrcieu.ac.uk/</ext-link>). The details of the GWAS data for both exposures and outcomes are provided in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. Consistent with the exposure populations, data for outcomes were also from European populations. Moreover, data for outcomes and exposures were from different studies, and population overlap was negligible. We used Cochran&#8217;s Q statistic [<xref ref-type="bibr" rid="CR21">21</xref>], MR-Egger regression [<xref ref-type="bibr" rid="CR22">22</xref>], and MR-PRESSO [<xref ref-type="bibr" rid="CR23">23</xref>] to assess heterogeneity and horizontal pleiotropy. Additionally, we conducted leave-one-out sensitivity test to judge the stability of the MR results by excluding IVs one by one.</p><p id="Par12">In addition, to examine the bi-directional causation between cancers and HCV infection, we analyzed 10 types of cancer as exposures and HCV infection as the outcome, using reverse MR analyses. To enhance the number of available instruments for each cancer type, we chose SNPs with a significance threshold of 5&#8201;&#215;&#8201;10<sup>&#8211;6</sup>.</p><p id="Par13">The study&#8217;s analytical procedures were conducted utilizing the &#8220;TwoSampleMR&#8221; (v0.5.7) and &#8220;MRPRESSO&#8221; (v1.0) packages within the R software environment (v4.1.3). The primary method of analysis for MR analysis was the inverse-variance weighted (IVW) [<xref ref-type="bibr" rid="CR24">24</xref>]. To account for multiple comparisons, we applied the Bonferroni correction to adjust the significance threshold, with a <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.005 (0.05/10 outcomes) indicating statistical significance and a <italic toggle="yes">P</italic>&#8201;between 0.05 and 0.005 suggesting a potential causal relationship. A <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05 suggested no evidence of heterogeneity or horizontal pleiotropy.</p></sec><sec id="Sec4"><title>Multivariable MR (MVMR) analysis and mediation analyses</title><p id="Par14">Individuals infected with HCV showed a higher prevalence of tobacco and alcohol use compared to those who are not infected [<xref ref-type="bibr" rid="CR25">25</xref>]. MVMR enabled us to evaluate the causal effects of multiple exposures on a single outcome, which could adjust potential confounding factors on MR [<xref ref-type="bibr" rid="CR26">26</xref>]. To ensure our findings were not influenced by confounding factors, we applied MVMR to detect the causal effects of HCV infection on extrahepatic cancers adjusted for smoking and drinking traits using the &#8220;TwoSampleMR&#8221; (v0.5.7) and &#8220;MendelianRandomization&#8221; (v0.9.0) R packages. The GWAS summary data on smoking and drinking traits were obtained from the GWAS &amp; Sequencing Consortium of Alcohol and Nicotine use (GSCAN) consortium [<xref ref-type="bibr" rid="CR27">27</xref>], with SNPs for these traits identified at a significance threshold of <italic toggle="yes">P</italic>&#8201;&lt;&#8201;5&#8201;&#215;&#8201;10<sup>&#8211;8</sup>.</p><p id="Par15">Additionally, we utilized two-step Mendelian Randomization (MR) approach to uncover possible intermediary variables between HCV infection and extrahepatic cancers. Prior research has demonstrated that HCV can infect immune effector cells, allowing it to evade host immune surveillance. Besides, HCV infection also has a multifaceted impact on metabolism, especially lipid metabolism, which may lead to the development of pro-oncogenic microenvironment. Based on these biological insights, we took immune cells, blood metabolites and plasma proteome as potential mediators. GWAS summary data for these potential mediators were obtained from the MRC IEU OpenGWAS database (<ext-link ext-link-type="uri" xlink:href="https://gwas.mrcieu.ac.uk/">https://gwas.mrcieu.ac.uk/</ext-link>) (Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>). The GWAS data for human blood metabolites, including amino acid, lipid, carbohydrate, nucleotide, fatty acid and peptide, was summarized from two European population studies, including 7,824 adult individuals [<xref ref-type="bibr" rid="CR28">28</xref>]. A total of 452 metabolites were included in this analysis. The GWAS data for human plasma proteome was obtained from INTERVAL study and IMPROVE study, encompassing 50,000 and 3,711 individuals respectively [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. For INTERVAL study, 3,282 proteins were included in the analysis. For IMPROVE study, 83 proteins were included in the analysis. The GWAS data for immune cells was derived from the SardiNIA project, which detected 731 immune cell traits on a total of 6,602 participants [<xref ref-type="bibr" rid="CR31">31</xref>]. To quantify the mediating effect, we calculated the percentage of mediation using the formula (&#946;1&#8201;&#215;&#8201;&#946;2/&#946;3), where &#946;1 denotes the causal effect from the exposure to the mediator, &#946;2 represents the causal effect from the mediator to the outcome, and &#946;3 represents the causal effect from the exposure to the outcome [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec5"><title>Colocalization analysis and transcriptomic analysis</title><p id="Par16">To explore the underlying biological mechanism of HCV infection leading to extrahepatic cancer, we conducted a colocalization analysis using the Sherlock algorithm [<xref ref-type="bibr" rid="CR33">33</xref>]. Sherlock is a computational algorithm that can predict genes with possible disease roles integrating information from the expression quantitative trait loci (eQTL) data and GWAS data. In this algorithm, the log Bayes Factor (LBF) value was calculated to assess the strength of evidence supporting a functional role for specific genes associated with SNPs [<xref ref-type="bibr" rid="CR34">34</xref>]. For our colocalization analysis, we used the GWAS data for HCV infection &#8220;GCST90041714&#8221; and the eQTL data for whole blood and liver from the Genotype-Tissue Expression (GTEx) (<ext-link ext-link-type="uri" xlink:href="https://www.gtexportal.org/home/">https://www.gtexportal.org/home/</ext-link> index.html). We applied the web tool Sherlock (<ext-link ext-link-type="uri" xlink:href="http://sherlock.ucsf.edu/submit.html">http://sherlock.ucsf.edu/submit.html</ext-link>) to complete colocalization analysis. HCV-associated susceptibility genes (HSGs) were obtained by combining genes from whole blood and liver eQTL data. Moreover, we conducted functional enrichment analysis for HSGs by the Metascape web tool (<ext-link ext-link-type="uri" xlink:href="https://metascape.org/gp/index.html#/main/step1)">https://metascape.org/gp/index.html#/main/step1)</ext-link> [<xref ref-type="bibr" rid="CR35">35</xref>]. We retrieved transcriptomic data from The Cancer Genome Atlas (TCGA) database (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>) to perform a pan-cancer analysis and develop a prognostic model for kidney cancer patients based on HSGs. Initially, the TCGAplot R package (v5.0.0) was utilized to perform pan-cancer analysis on the top HCV susceptibility genes (<italic toggle="yes">IRF5</italic>), including <italic toggle="yes">IRF5</italic> mRNA differential expression comparing tumor and normal tissues and Kaplan-Meier (KM) survival analysis [<xref ref-type="bibr" rid="CR36">36</xref>]. Furthermore, we downloaded gene expression data and survival data of kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), and kidney renal papillary cell carcinoma (KIRP) from UCSC Xena (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/datapages/">https://xenabrowser.net/datapages/</ext-link>) to construct a model to predict kidney cancer prognosis. A percentage of 50% samples were randomly assigned to the training cohort to screen HSGs to establish the model, and the other 50% were assigned to the validation cohort to evaluate the model&#8217;s performance [<xref ref-type="bibr" rid="CR37">37</xref>]. Then, we applied univariable cox regression, least absolute shrinkage and selection operator (LASSO) regression and multivariable cox regression to select HSGs which were associated with kidney cancer prognosis using the &#8220;survival&#8221; (v3.5-5) [<xref ref-type="bibr" rid="CR38">38</xref>] and &#8220;glmnet&#8221; (v4.1-8) [<xref ref-type="bibr" rid="CR39">39</xref>] packages. LASSO regression used 10-fold cross-validation to optimize lambda by minimizing mean squared error. Finally, a risk score was calculated based on the regression coefficients from the multivariate Cox analysis: Risk score&#8201;=&#8201;the expression levels of gene A &#215; coefficient A&#8201;+&#8201;the expression levels of gene B &#215; coefficient B + &#8230;&#8230; + the expression levels of gene N &#215; coefficient N. The patients were divided into high-risk and low-risk groups by the median of the risk score. To validate the model&#8217;s ability to predict prognosis, we conducted KM survival analysis using the &#8220;survminer&#8221; (v0.4.9) package, concordance (C)-index with the &#8220;rms&#8221; (v6.7-1) package and time-dependent receiver operating characteristic curves (ROC) by the &#8220;timeROC&#8221; (v0.4) package. In addition, we performed multivariable cox regression for risk score, age, gender and tumor stage to explore if the risk score is an independent prognostic factor. We also drew nomograms and calibration charts using the &#8220;rms&#8221; (v6.7-1) and &#8220;regplot&#8221; (v1.1) R packages. All forest maps in this article are drawn based on the &#8220;forestplot&#8221; (v3.1.3) package.</p></sec><sec id="Sec6"><title>GRS analysis</title><p id="Par17">The GRS model could measure the genetic risk of individual traits or complex diseases by integrating SNPs locus information associated with complex diseases and superimposing small effects on each SNP, used for early prevention and precise diagnosis of complex diseases [<xref ref-type="bibr" rid="CR40">40</xref>]. To validate the MR results, we implemented a GRS analysis by individual-level data from UK Biobank (project ID: 106528). 18 SNPs associated with HCV infection in the MR analysis and their &#946; were used for this analysis. Firstly, we extracted SNPs data and demographic information of 2,303 patients with kidney cancer (Field ID: 40006, ICD10 coding: C64) by PLINK and R softwares. Secondly, to select age- and sex-matched cancer-free controls, we applied the &#8220;MatchIt&#8221; R package (v4.5.5) based on a nearest neighbor method with a 1:2 case-control ratio [<xref ref-type="bibr" rid="CR41">41</xref>]. Then, the weighted GRS of each person was calculated using the following formula: <inline-formula id="IEq1"><alternatives><tex-math id="d33e450">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:GRS=\:{\sum\:}_{i=1}^{n}{\beta\:}_{i}{SNP}_{i}$$\end{document}</tex-math><inline-graphic xlink:href="13027_2025_693_Article_IEq1.gif"/></alternatives></inline-formula>, where n represented the number of SNPs, <inline-formula id="IEq2"><alternatives><tex-math id="d33e456">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\beta\:}_{i}\:$$\end{document}</tex-math><inline-graphic xlink:href="13027_2025_693_Article_IEq2.gif"/></alternatives></inline-formula>represented the &#946; of this SNP in MR analysis, <inline-formula id="IEq3"><alternatives><tex-math id="d33e462">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{SNP}_{i}$$\end{document}</tex-math><inline-graphic xlink:href="13027_2025_693_Article_IEq3.gif"/></alternatives></inline-formula> represented the number of risk alleles [<xref ref-type="bibr" rid="CR42">42</xref>]. Participants with missing SNPs typing data or demographic data were excluded from this study. In addition, we utilized multivariable logistic regression to estimate the effect size of HCV infection on kidney cancer after adjusting age (Field ID: 21022), sex (Field ID: 31), body mass index (BMI) (Field ID: 21001), smoking (Field ID: 20116), alcohol intake frequency (Field ID: 1558), race (Field ID: 21000) using R software (v4.1.3). Considering that individuals from different ancestral backgrounds have systematic frequency differences across SNP loci that are associated with disease risk or exposure factors, UK Biobank calculated principal components to control population stratification, which increased the credibility of causal inference [<xref ref-type="bibr" rid="CR43">43</xref>]. According to previous literature, the tops 10 principal components (Field ID: 22009) was also included in adjustive variable [<xref ref-type="bibr" rid="CR41">41</xref>]. <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>MR analysis revealed a cause&#8209;effect relationship between HCV infection and kidney cancer</title><p id="Par18">According to the screening criteria applied, we selected 18 SNPs that were strongly associated with HCV infection as IVs (Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>). The F values for these IVs were notably higher than the threshold of 10, ranging from 19.66 to 29.02, implying that there was no bias of weak IVs. We also verified that our IVs were not directly related to common confounders (including alcohol consumption, smoking status, physical activity, and body mass index) or the ten site-specific cancers (including brain glioblastoma, lung cancer, esophageal carcinoma, stomach cancer, colorectal cancer, pancreatic cancer, kidney cancer, breast cancer, prostate cancer, and ovarian cancer) explored in our study by searching on PhenoScanner database. None of the 18 SNPs were excluded from the analysis. To avoid or reduce sample overlap, we selected the GWAS summary data for extrahepatic cancers from studies other than UK Biobank to perform two-sample MR, including the FINNGEN [<xref ref-type="bibr" rid="CR44">44</xref>], international Lung Cancer Consortium (ILCCO) [<xref ref-type="bibr" rid="CR45">45</xref>], Breast Cancer Association Consortium (BCAC) [<xref ref-type="bibr" rid="CR46">46</xref>], Ovarian Cancer Association Consortium (OCAC) [<xref ref-type="bibr" rid="CR47">47</xref>] and Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome Consortium (PRACTICAL) [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par19">Using the IVW approach in the univariable MR analysis, we detected a suggestive causal relationship between increased HCV infection risk and the development of malignant neoplasm of kidney (except renal pelvis), with an odds ratio (OR) of 1.060 and 95% confidence interval (CI) from 1.006 to 1.118 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.029; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). There was no evidence for heterogeneity (<italic toggle="yes">P</italic><sub>Cochran&#8217;s Q</sub> = 0.113 and <italic toggle="yes">P</italic><sub>MR&#8722;Egger</sub>=0.365) or horizontal pleiotropy (<italic toggle="yes">P</italic>&#8201;<sub>MR&#8722;PRESSO</sub> = 0.105) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). The robustness of results was confirmed by the leave-one-out sensitivity test (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref>). The results showed that HCV infection was not causally associated with the development of other tumors. Further reverse MR analyses, using HCV infection as the outcome and 10 extrahepatic cancers as exposures, showed no evidence of reverse causality (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B).</p><p id="Par20">Considering that smoking and drinking might be important confounders of the association, we conducted MVMR to simultaneously estimate the direct effect of HCV infection on cancers conditioned on smoking and drinking status. All the IVs used for MVMR were with a F&#8201;&gt;&#8201;10 and listed in Supplementary Table <xref rid="MOESM1" ref-type="media">4</xref>. The results showed a significant positive causal influence for genetically predicted HCV infection on the risk of kidney cancer (OR&#8201;=&#8201;1.074, 95% CI: 1.027&#8211;1.124, <italic toggle="yes">P</italic>&#8201;=&#8201;0.002) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C). As well, there was no evidence of heterogeneity (<italic toggle="yes">P</italic><sub>Cochran&#8217;s Q</sub> = 0.365 and <italic toggle="yes">P</italic><sub>MR&#8722;Egger</sub>=0.642) or horizontal pleiotropy (<italic toggle="yes">P</italic>&#8201;<sub>MR&#8722;PRESSO</sub> = 0.501) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C). Except for this, after adjusting for smoking and drinking, genetic prediction of HCV infection showed no potential causative effect on development of other 9 types of cancer.</p><p id="Par21">To investigate the potential mediators influencing the causal effects of HCV infection on kidney cancer, we conducted two-step Mendelian randomization analyses, examining immune cells, blood metabolites, and plasma proteome as mediators. Our analysis identified several key mediators with substantial proportions: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (mediated proportion 11.14%), DNA-3-methyladenine glycosylase (mediated proportion 4.99%), aspartylphenylalanine (mediated proportion 28.67%), CD25 on naive-mature B cell (mediated proportion 10.27%) and SSC-A on HLA DR&#8201;+&#8201;CD4&#8201;+&#8201;T cell (mediated proportion 6.40%). Detailed results are provided in Supplementary Table <xref rid="MOESM1" ref-type="media">5</xref>.</p><p id="Par22">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The results of MR and sensitivity analysis between HCV infection and 10 extrahepatic cancers using (<bold>A</bold>) IVW method, (<bold>B</bold>) reverse MR and (<bold>C</bold>) MVMR adjusting for smoking and drinking traits</p></caption><graphic id="d33e588" position="float" orientation="portrait" xlink:href="13027_2025_693_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec9"><title>Colocalization analysis identified HSGs that might drive kidney cancer</title><p id="Par23">Genetic variants influence disease risk mostly by modulating gene expression [<xref ref-type="bibr" rid="CR49">49</xref>]. To further find HSGs, we used the GWAS data for HCV infection &#8220;GCST90041714&#8221; and eQTL data &#8220;GTEx V7 Whole Blood&#8221; and &#8220;GTEx V7 Liver&#8221; to conduct colocalization analysis. We identified 314 HSGs in the whole blood and 649 HSGs in the liver, of which 27 were common (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, LBF&#8201;&gt;&#8201;0; Table&#160;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). Notable genes included <italic toggle="yes">IRF5</italic> (LBF&#8201;=&#8201;6.46, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), <italic toggle="yes">OCEL1</italic> (LBF&#8201;=&#8201;6.23, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), and <italic toggle="yes">SLC22A7</italic> (LBF&#8201;=&#8201;5.52, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Enrichment analysis indicated that these HSGs primarily participate in the metabolism of lipids, hemostasis and regulation of proteolysis (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B). Among 936 HSGs, <italic toggle="yes">IRF5</italic> consistently emerged as a prominent risk gene for HCV infection across both whole blood and liver eQTL datasets. To investigate the role of <italic toggle="yes">IRF5</italic> in cancer, we assessed its expression in tumor and corresponding normal tissues and discovered that <italic toggle="yes">IRF5</italic> was abnormally expressed in 16 common malignancies (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C, Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref>A). Furthermore, higher <italic toggle="yes">IRF5</italic> expression levels were significantly linked to poorer overall survival in patients with lower-grade glioma (LGG) and uveal melanoma (UVM) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>D-E). Then, we found that <italic toggle="yes">IRF5</italic> was positively correlated with immune score, stromal score, and estimate score in most tumors (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref>B). We also found that <italic toggle="yes">IRF5</italic> expression levels correlated with a variety of immune cells infiltration and checkpoint-associated genes, such as macrophages M2, natural killer cells (NK cells), T cells regulatory (Tregs), CD274 and cytotoxic T-lymphocyte associated protein 4 (CTLA4) (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref>C-D).</p><p id="Par24">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>The results by colocalization analysis of eQTL data for liver and GWAS data for HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Gene</th><th align="left" colspan="1" rowspan="1">SNP</th><th align="left" colspan="1" rowspan="1">Proximity</th><th align="left" colspan="1" rowspan="1">Location</th><th align="left" colspan="1" rowspan="1">eQTL pval</th><th align="left" colspan="1" rowspan="1">GWAS pval</th><th align="left" colspan="1" rowspan="1">LBF</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">IRF5</italic>
</td><td align="left" colspan="1" rowspan="1">rs10279821</td><td align="left" colspan="1" rowspan="1">cris</td><td align="left" colspan="1" rowspan="1">chr7: 128,470,783</td><td align="left" colspan="1" rowspan="1">3.79E-15</td><td align="left" colspan="1" rowspan="1">2.66E-06</td><td char="." align="char" colspan="1" rowspan="1">6.45553</td><td align="left" colspan="1" rowspan="1">8.40E-05</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">OCEL1</italic>
</td><td align="left" colspan="1" rowspan="1">rs5012765</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr22: 43,568,127</td><td align="left" colspan="1" rowspan="1">5.52E-07</td><td align="left" colspan="1" rowspan="1">5.22E-04</td><td char="." align="char" colspan="1" rowspan="1">6.22824</td><td align="left" colspan="1" rowspan="1">1.20E-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">OCEL1</italic>
</td><td align="left" colspan="1" rowspan="1">rs2288542</td><td align="left" colspan="1" rowspan="1">cris</td><td align="left" colspan="1" rowspan="1">chr19: 17,198,223</td><td align="left" colspan="1" rowspan="1">5.35E-05</td><td align="left" colspan="1" rowspan="1">1.41E-03</td><td char="." align="char" colspan="1" rowspan="1">6.22824</td><td align="left" colspan="1" rowspan="1">1.20E-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">SLC22A7</italic>
</td><td align="left" colspan="1" rowspan="1">rs16992816</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr22: 43,568,066</td><td align="left" colspan="1" rowspan="1">1.10E-06</td><td align="left" colspan="1" rowspan="1">5.26E-04</td><td char="." align="char" colspan="1" rowspan="1">5.51947</td><td align="left" colspan="1" rowspan="1">2.82E-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">SLC22A7</italic>
</td><td align="left" colspan="1" rowspan="1">rs26475</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr5: 11,275,453</td><td align="left" colspan="1" rowspan="1">1.59E-06</td><td align="left" colspan="1" rowspan="1">7.84E-03</td><td char="." align="char" colspan="1" rowspan="1">5.51947</td><td align="left" colspan="1" rowspan="1">2.82E-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">SLC22A7</italic>
</td><td align="left" colspan="1" rowspan="1">rs16992816</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr8: 5,663,466</td><td align="left" colspan="1" rowspan="1">5.26E-04</td><td align="left" colspan="1" rowspan="1">3.28E-02</td><td char="." align="char" colspan="1" rowspan="1">5.51947</td><td align="left" colspan="1" rowspan="1">2.82E-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">RAC2</italic>
</td><td align="left" colspan="1" rowspan="1">rs11089825</td><td align="left" colspan="1" rowspan="1">cris</td><td align="left" colspan="1" rowspan="1">chr22: 35,905,344</td><td align="left" colspan="1" rowspan="1">9.30E-05</td><td align="left" colspan="1" rowspan="1">6.30E-05</td><td char="." align="char" colspan="1" rowspan="1">5.19804</td><td align="left" colspan="1" rowspan="1">4.54E-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">RAC2</italic>
</td><td align="left" colspan="1" rowspan="1">rs7610909</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr3: 76,515,609</td><td align="left" colspan="1" rowspan="1">7.13E-06</td><td align="left" colspan="1" rowspan="1">1.34E-02</td><td char="." align="char" colspan="1" rowspan="1">5.19804</td><td align="left" colspan="1" rowspan="1">4.54E-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">ZBTB7A</italic>
</td><td align="left" colspan="1" rowspan="1">rs845852</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr6: 106,253,078</td><td align="left" colspan="1" rowspan="1">5.28E-06</td><td align="left" colspan="1" rowspan="1">7.59E-05</td><td char="." align="char" colspan="1" rowspan="1">5.14718</td><td align="left" colspan="1" rowspan="1">4.92e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">ZBTB7A</italic>
</td><td align="left" colspan="1" rowspan="1">rs11074352</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr16: 9,628,802</td><td align="left" colspan="1" rowspan="1">1.87E-06</td><td align="left" colspan="1" rowspan="1">4.96E-02</td><td char="." align="char" colspan="1" rowspan="1">5.14718</td><td align="left" colspan="1" rowspan="1">4.92e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">ZNF273</italic>
</td><td align="left" colspan="1" rowspan="1">rs11089825</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr22: 35,905,344</td><td align="left" colspan="1" rowspan="1">1.03E-06</td><td align="left" colspan="1" rowspan="1">6.30E-05</td><td char="." align="char" colspan="1" rowspan="1">5.05725</td><td align="left" colspan="1" rowspan="1">5.38e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">GTSE1</italic>
</td><td align="left" colspan="1" rowspan="1">rs3807306</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr7: 128,367,916</td><td align="left" colspan="1" rowspan="1">5.24E-06</td><td align="left" colspan="1" rowspan="1">6.65E-04</td><td char="." align="char" colspan="1" rowspan="1">4.80137</td><td align="left" colspan="1" rowspan="1">7.86e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">GTSE1</italic>
</td><td align="left" colspan="1" rowspan="1">rs903056</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr3: 14,785,294</td><td align="left" colspan="1" rowspan="1">2.50E-06</td><td align="left" colspan="1" rowspan="1">1.08E-02</td><td char="." align="char" colspan="1" rowspan="1">4.80137</td><td align="left" colspan="1" rowspan="1">7.86e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">GTSE1</italic>
</td><td align="left" colspan="1" rowspan="1">rs7652589</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr3: 123,371,778</td><td align="left" colspan="1" rowspan="1">2.45E-07</td><td align="left" colspan="1" rowspan="1">9.57E-02</td><td char="." align="char" colspan="1" rowspan="1">4.80137</td><td align="left" colspan="1" rowspan="1">7.86e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">NRG1</italic>
</td><td align="left" colspan="1" rowspan="1">rs12815546</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr12: 25,273,809</td><td align="left" colspan="1" rowspan="1">5.72E-07</td><td align="left" colspan="1" rowspan="1">1.16E-03</td><td char="." align="char" colspan="1" rowspan="1">4.78349</td><td align="left" colspan="1" rowspan="1">8.09e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">NRG1</italic>
</td><td align="left" colspan="1" rowspan="1">rs11106474</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr12: 91,151,341</td><td align="left" colspan="1" rowspan="1">4.23E-06</td><td align="left" colspan="1" rowspan="1">1.85E-02</td><td char="." align="char" colspan="1" rowspan="1">4.78349</td><td align="left" colspan="1" rowspan="1">8.09e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">NRG1</italic>
</td><td align="left" colspan="1" rowspan="1">rs6070149</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr20: 55,563,144</td><td align="left" colspan="1" rowspan="1">6.18E-06</td><td align="left" colspan="1" rowspan="1">2.99E-02</td><td char="." align="char" colspan="1" rowspan="1">4.78349</td><td align="left" colspan="1" rowspan="1">8.09e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">CASP4</italic>
</td><td align="left" colspan="1" rowspan="1">rs5012765</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr22: 43,568,127</td><td align="left" colspan="1" rowspan="1">2.07E-07</td><td align="left" colspan="1" rowspan="1">5.22E-04</td><td char="." align="char" colspan="1" rowspan="1">4.62598</td><td align="left" colspan="1" rowspan="1">9.94e-04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">CASP4</italic>
</td><td align="left" colspan="1" rowspan="1">rs920041</td><td align="left" colspan="1" rowspan="1">trans</td><td align="left" colspan="1" rowspan="1">chr11: 38,434,117</td><td align="left" colspan="1" rowspan="1">1.70E-07</td><td align="left" colspan="1" rowspan="1">1.08E-01</td><td char="." align="char" colspan="1" rowspan="1">4.62598</td><td align="left" colspan="1" rowspan="1">9.94e-04</td></tr></tbody></table></table-wrap>
</p><p id="Par25">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>The HSGs that might drive kidney cancer identified by colocalization analysis. (<bold>A</bold>) The venn diagram showing HSGs obtained from whole blood and liver eQTL data. (<bold>B</bold>) The results of enrichment analysis on HSGs. (<bold>C</bold>) Examination of <italic toggle="yes">IRF5</italic> mRNA expression in tumor samples versus paired non-tumor normal specimens from TCGA. KM curves illustrating the relationship between <italic toggle="yes">IRF5</italic> expression and OS for (<bold>D</bold>) LGG and (<bold>E</bold>) UVM patients</p></caption><graphic id="d33e1134" position="float" orientation="portrait" xlink:href="13027_2025_693_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec10"><title>Transcriptomic analysis established a novel predictive prognostic model based on HSGs</title><p id="Par26">In establishing the prognostic model, all 441 samples from the training cohort were utilized. Initially, univariable Cox regression analysis identified 241 HSGs associated with survival of kidney cancer (Supplementary Table <xref rid="MOESM1" ref-type="media">6</xref>). Subsequently, the LASSO regression analysis for the above 241 HSGs were performed using LASSO regression, with coefficient paths across the logarithmic lambda spectrum illustrated in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A. The optimal lambda value (lambda.min) was determined through 10-fold cross-validation, maximizing the area under the receiver operating characteristic curve (AUC-ROC) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B). This approach identified three robust HSGs: <italic toggle="yes">GTSE1</italic>, <italic toggle="yes">TOLLIP</italic> and <italic toggle="yes">SPOCD1.</italic> The prognostic risk score was calculated using the following formula: risk score = (1.34 &#215; <italic toggle="yes">GTSE1</italic> expression) &#8211; (2.38 &#215; <italic toggle="yes">TOLLIP</italic> expression) + (0.74 &#215; <italic toggle="yes">SPOCD1</italic> expression). The KM survival analysis revealed a markedly lower OS among patients in the high-risk group when compared to those in the low-risk group (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Similarly, we proceeded to evaluate the predictive efficacy of the prognostic model in both the validation cohort and the entire cohorts. The KM survival curves, as presented in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C, demonstrated a significantly poorer prognosis for high-risk patients in the validation cohort (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). In the entire cohort, the model yieled AUCs of 0.768 (95% CI: 0.703&#8211;0.828), 0.712 (95% CI: 0.657&#8211;0.760), and 0.736 (95% CI: 0.691&#8211;0.788) for predicting survival at 1 year, 3 years and 5 years, respectively (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>D). In the training set, the model achieved AUCs of 0.750 (95% CI: 0.651&#8211;0.846), 0.703 (95% CI: 0.618&#8211;0.767), and 0.700 (95% CI: 0.635&#8211;0.782) for 1-, 3-, and 5-year survival predictions, respectively (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3</xref>A). In the validation set, the corresponding AUCs were 0.786 (95% CI: 0.706&#8211;0.861), 0.724 (95% CI: 0.651&#8211;0.796), and 0.764 (95% CI: 0.702&#8211;0.828), confirming consistent discriminative performance across cohorts (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3</xref>B). The absolute difference in AUCs between the training and validation sets was &lt;&#8201;10% at each time point (1-year: 4.8%; 3-year: 3.0%; 5-year: 9.1%), indicating negligible over-fitting. Then, to investigate the predictive performance of the risk score in three subtypes of kidney cancer patients, we conducted KM survival analyses in patients with KICH, KIRC and KIRP and also found a worse prognosis in high-risk patients in all three subtypes of kidney cancer (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>E-G).</p><p id="Par27">In addition, to verify whether the risk score was a predictive factor independent of other clinical elements such as gender, age at diagnosis, and clinical stage, we subsequently performed univariable and multivariate Cox regression analyses in the entire cohort. To our surprise, the prognostic model was indicated as an independent prognostic indicator not only in the univariable Cox regression (Hazard Ratio (HR)&#8201;=&#8201;1.141, 95% CI: 1.116&#8211;1.167, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) but also in the multivariate Cox regression (HR&#8201;=&#8201;1.118, 95% CI: 1.099&#8211;1.146, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4</xref>A-B). Meanwhile, we developed a nomogram based on the risk scores as well as the above clinical elements in all the cohort (Supplementary Fig.&#160;4C). The AUCs of the nomogram were 0.883 (95% CI: 0.851&#8211;0.915), 0.812 (95% CI: 0.772&#8211;0.852), and 0.783 (95% CI: 0.737&#8211;0.828) for 1-, 3-, and 5-year survival times, respectively (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4</xref>D). The C-index was 0.713. Furthermore, the calibration curve demonstrated an excellent predictive performance at 1-, 3-, and 5-year OS (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4</xref>E).</p><p id="Par28">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Development of a novel predictive prognostic model based on HSGs using the TCGA training cohort. (<bold>A</bold>) LASSO regression analysis and (<bold>B</bold>) LASSO coefficient profiles of HSGs. (<bold>C</bold>) KM curves illustrating OS outcomes in the validation cohort, divided by high- and low-risk score groups. (<bold>D</bold>) The AUCs of the time-dependent ROC curves in the entire cohort. The KM curves of risk score for OS outcomes in patients with (<bold>E</bold>) KICH, (<bold>F</bold>) KIRC and (<bold>G</bold>) KIRP</p></caption><graphic id="d33e1238" position="float" orientation="portrait" xlink:href="13027_2025_693_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec11"><title>GRS analysis confirmed the causal relationship between HCV infection and kidney cancer</title><p id="Par29">In total, 3,857 individuals from UK Biobank were selected in the GRS analysis to conduct case-control study, which included 1,290 cases diagnosed with malignant neoplasm of kidney (except renal pelvis) and 2,567 non-cancer controls. Patients and cancer-free controls were age-matched, with a mean age of 61.0 years at recruitment (<italic toggle="yes">P</italic>&#8201;=&#8201;0.967). Moreover, their ethnic backgrounds (<italic toggle="yes">P</italic>&#8201;=&#8201;0.521) and sex proportion (<italic toggle="yes">P</italic>&#8201;=&#8201;0.976) were similar. However, the case cohort had a significantly higher proportion of previous and current smokers (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), higher alcohol intake frequency (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and higher BMI (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) than controls (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). As expected, the weighted GRS of HCV infection revealed a significant casual effect on kidney cancer risk (OR&#8201;=&#8201;1.049, 95% CI&#8201;=&#8201;1.001&#8211;1.098, <italic toggle="yes">P</italic>&#8201;=&#8201;0.043) in the multivariable logistic regression, which was consistent with the MR results.</p><p id="Par30">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>The basic characteristics of participants in the GRS analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Basic characteristics</th><th align="left" colspan="1" rowspan="1">Controls (<italic toggle="yes">n</italic>&#8201;=&#8201;2567)</th><th align="left" colspan="1" rowspan="1">Cases (<italic toggle="yes">n</italic>&#8201;=&#8201;1290)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Sex</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.976</td></tr><tr><td align="left" colspan="1" rowspan="1">Male, n (%)</td><td char="." align="char" colspan="1" rowspan="1">934 (36.385)</td><td char="." align="char" colspan="1" rowspan="1">470 (36.434)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Female, n (%)</td><td char="." align="char" colspan="1" rowspan="1">1633 (63.615)</td><td char="." align="char" colspan="1" rowspan="1">820 (63.566)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Age</bold>,<bold> y (IQR)</bold></td><td char="." align="char" colspan="1" rowspan="1">61.000 (56.000,65.000)</td><td char="." align="char" colspan="1" rowspan="1">61.000 (56.000,65.000)</td><td char="." align="char" colspan="1" rowspan="1">0.967</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Race</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.521</td></tr><tr><td align="left" colspan="1" rowspan="1">White, n (%)</td><td char="." align="char" colspan="1" rowspan="1">2392 (93.183)</td><td char="." align="char" colspan="1" rowspan="1">1204 (93.333)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mixed, n (%)</td><td char="." align="char" colspan="1" rowspan="1">85 (3.311)</td><td char="." align="char" colspan="1" rowspan="1">46 (3.566)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Asian or Asian British, n (%)</td><td char="." align="char" colspan="1" rowspan="1">62 (2.415)</td><td char="." align="char" colspan="1" rowspan="1">28 (2.171)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Black or Black British, n (%)</td><td char="." align="char" colspan="1" rowspan="1">7 (0.273)</td><td char="." align="char" colspan="1" rowspan="1">2 (0.155)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Other ethnic group, n (%)</td><td char="." align="char" colspan="1" rowspan="1">9 (0.351)</td><td char="." align="char" colspan="1" rowspan="1">1 (0.078)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Other, n (%)</td><td char="." align="char" colspan="1" rowspan="1">12 (0.467)</td><td char="." align="char" colspan="1" rowspan="1">9 (0.698)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Smoking</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Never, n (%)</td><td char="." align="char" colspan="1" rowspan="1">1348 (52.513)</td><td char="." align="char" colspan="1" rowspan="1">595 (46.124)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Previous, n (%)</td><td char="." align="char" colspan="1" rowspan="1">980 (38.177)</td><td char="." align="char" colspan="1" rowspan="1">534 (41.395)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Current, n (%)</td><td char="." align="char" colspan="1" rowspan="1">239 (9.310)</td><td char="." align="char" colspan="1" rowspan="1">161 (12.481)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Alcohol intake</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Daily or almost daily, n (%)</td><td char="." align="char" colspan="1" rowspan="1">601 (23.413)</td><td char="." align="char" colspan="1" rowspan="1">253 (19.612)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Three or four times a week, n (%)</td><td char="." align="char" colspan="1" rowspan="1">639 (24.893)</td><td char="." align="char" colspan="1" rowspan="1">252 (19.535)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Once or twice a week, n (%)</td><td char="." align="char" colspan="1" rowspan="1">618 (24.075)</td><td char="." align="char" colspan="1" rowspan="1">348 (26.977)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">One to three times a month, n (%)</td><td char="." align="char" colspan="1" rowspan="1">255 (9.934)</td><td char="." align="char" colspan="1" rowspan="1">152 (11.783)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Special occasions only, n (%)</td><td char="." align="char" colspan="1" rowspan="1">252 (9.817)</td><td char="." align="char" colspan="1" rowspan="1">170 (13.178)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Never, n (%)</td><td char="." align="char" colspan="1" rowspan="1">202 (7.869)</td><td char="." align="char" colspan="1" rowspan="1">115 (8.915)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><bold>BMI</bold>,<bold> kg/m</bold><sup><bold>2</bold></sup>
<bold>(IQR)</bold></td><td char="." align="char" colspan="1" rowspan="1">27.150 (24.656,29.871)</td><td char="." align="char" colspan="1" rowspan="1">28.185 (25.575,31.664)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table></table-wrap>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par31">For the first time, we employed both univariable MR and MVMR methods to systematically investigate the causal relationship between HCV infection and extrahepatic cancers. These findings were further corroborated by GRS analysis. Our study suggested a causative effect for HCV infection on increased kidney cancer risk both in univariable MR and MVMR. While earlier observational studies have explored the connection between HCV and kidney cancer, their findings have been inconsistent [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. A cohort study by Anders H. Nyberg et al. illustrated that patients with HCV had an increased risk of renal cancer [<xref ref-type="bibr" rid="CR52">52</xref>]. However, this association was not observed in another case-control study [<xref ref-type="bibr" rid="CR53">53</xref>]. Given that MR can avoid bias commonly presented in conventional observational studies and perform well in causal interpretation, we therefore designed this MR analysis and found suggestive causal effect of HCV infection on kidney cancer in univariable MR and significant causal effect after adjusting for smoking and drinking factors in MVMR, both without obvious heterogeneity and horizontal pleiotropy. This result was supported by a recent meta-analysis indicating that HCV infection is associated with an increased risk of renal cell cancer (RCC), based on 11 epidemiological studies [<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par32">Our findings did not indicate a causal link between HCV infection and other extrahepatic cancers excluding kidney cancer, such as brain glioblastoma cancer, lung cancer, esophageal cancer, stomach cancer, CRC, pancreatic cancer, breast cancer, PCa and ovarian cancer. Similarly, a meta-analysis involving 1,939,164 participants did not show sufficient evidence to support the association between HCV infection and an increased risk of CRC [<xref ref-type="bibr" rid="CR54">54</xref>]. Another meta-analysis involving 1,989,1233 patients did not identify a significant relationship between HCV and PCa [<xref ref-type="bibr" rid="CR51">51</xref>], which was further corroborated by recent cross-sectional studies utilizing the National Health and Nutrition Examination Survey (NHANES) database [<xref ref-type="bibr" rid="CR55">55</xref>]. It is important to note that, although our MR results did not support a causal role for HCV infection in these cancers, further investigations are still necessary to validate our findings.</p><p id="Par33">The underlying mechanisms by which HCV infection leading to kidney cancer remain to be illuminated. On the one hand, based on previous evidence that kidney tissues can express CD81, a key receptor by which HCV infects hepatocytes and B lymphocytes and serves as a host for HCV replication, the virus may exert a direct oncogenic effect through HCV viral proteins [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Similar to HCV-induced liver cancer, HCV&#8217;s core proteins, NS3 and NS5A, may also play a parallel role in carcinogenesis in the kidney [<xref ref-type="bibr" rid="CR1">1</xref>]. NY-REN-54 was speculated as another key protein linking HCV and RCC, which can impair the autophagy response through the mechanism of the ubiquitin-protein ligase and in turn drive cancer development [<xref ref-type="bibr" rid="CR58">58</xref>]. In addition, long-term HCV infection may induce alterations in host cell epigenetics, which may persist after viral clearance [<xref ref-type="bibr" rid="CR9">9</xref>]. On the other hand, immune system disorders caused by HCV infection may be the main culprit in the development of kidney cancer [<xref ref-type="bibr" rid="CR59">59</xref>]. The infection of HCV resulted in chronic antigenic stimulation and CD8&#8201;+&#8201;T cells exhaustion, which was crucial in anti-tumor immune effect and was reported as a predictor of poor prognosis in RCC [<xref ref-type="bibr" rid="CR59">59</xref>&#8211;<xref ref-type="bibr" rid="CR61">61</xref>].</p><p id="Par34">Additionally, we conducted a two-step MR analysis to explore mediators between HCV infection and kidney cancer. The biological roles of these mediators have been extensively studied in the contexts of immunomodulation, metabolic regulation and cancer. For example, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (ARC), also referred to as CD38, primarily facilitates the production of cyclic ADP-ribose (cADPR) from nicotinamide adenine dinucleotide (NAD+), while also degrading cADPR [<xref ref-type="bibr" rid="CR62">62</xref>]. This enzyme plays a crucial role in regulating extracellular nucleotide homeostasis and intracellular calcium levels, thereby affecting cell proliferation and apoptosis [<xref ref-type="bibr" rid="CR63">63</xref>]. Numerous studies have highlighted how the CD38-NAD&#8201;+&#8201;axis influences metabolic reprogramming of T cells within the tumor microenvironment and contributes to the drug resistance often seen with PD-1/PD-L1 checkpoint inhibitors [<xref ref-type="bibr" rid="CR64">64</xref>]. Our findings offer new insights into the mechanisms that connect HCV infection to kidney cancer.</p><p id="Par35">Based on colocalization analysis, we identified a key HSG, <italic toggle="yes">IRF5</italic>. Our pan-cancer analysis found that the expression levels of <italic toggle="yes">IRF5</italic> were significantly higher in tumor tissues of KIRC and KIRP, two main pathological types of kidney tumors, when compared with normal tissues. As an important transcription factor that regulates both the innate and adaptive immune responses, <italic toggle="yes">IRF5</italic> facilitates the production of proinflammatory cytokines in response to pathogens, including interleukin (IL)-6, IL-12, IL-23, and tumor necrosis factor (TNF)-&#945; [<xref ref-type="bibr" rid="CR65">65</xref>]. These evidence may shed light on the underlying mechanisms in HCV associated extrahepatic cancers. Many prior studies had reported the role of <italic toggle="yes">IRF5</italic> on cancer development. For example, Qi Bai et al. found that patients with non-metastatic clear cell renal cell carcinoma (ccRCC) who expressed higher levels of <italic toggle="yes">IRF5</italic> had poorer prognoses [<xref ref-type="bibr" rid="CR66">66</xref>]. A recent study demonstrated that <italic toggle="yes">IRF5</italic> promotes the metastasis of gastric cancer cells by inducing the degradation of Wnt5a and E-cadherin [<xref ref-type="bibr" rid="CR67">67</xref>]. In contrast, <italic toggle="yes">IRF5</italic> has also been described as a tumor suppressor in certain cancer types. For instance, pancreatic adenocarcinoma patients with higher levels of tumor-infiltrating lymphocytes exhibiting elevated mRNA expression of <italic toggle="yes">IRF5</italic> had better prognoses [<xref ref-type="bibr" rid="CR68">68</xref>]. The suppressed <italic toggle="yes">IRF5</italic>, resulting from overexpression of <italic toggle="yes">MYC</italic>, could lead to the loss of IFN signaling and promote the progression of pancreatic ductal adenocarcinoma [<xref ref-type="bibr" rid="CR69">69</xref>]. For breast cancer, Erica Maria Pimenta et al. confirmed that <italic toggle="yes">IRF5</italic> can regulate CXCL13 expression, enhancing the recruitment of CD19&#8201;+&#8201;CXCR5&#8201;+&#8201;B cells and CD4&#8201;+&#8201;CXCR5&#8201;+&#8201;T cells, thereby boosting the anti-tumor response in human breast adenocarcinoma cell lines [<xref ref-type="bibr" rid="CR70">70</xref>]. These findings may help explain the negative association between genetic susceptibility to HCV infection and pancreatic and breast cancer observed in our MVMR results.</p><p id="Par36">Enrichment analysis showed that pathways involved in lipid metabolism were significantly linked to HCV-related kidney cancer risk. HCV is a well-established &#8220;metabolic virus&#8221; whose life cycle is tightly intertwined with host lipid metabolism [<xref ref-type="bibr" rid="CR71">71</xref>]. HCV circulates as a lipid-rich particle that enters host cells via lipoprotein receptors, up-regulates lipid biosynthesis and impairs degradation, leading to hepatic steatosis, systemic dyslipidaemia and accelerated atherosclerosis [<xref ref-type="bibr" rid="CR71">71</xref>]. Chronic HCV infection predisposes patients to lipid dysregulation, and the kidney may similarly undergo metabolic reprogramming as a recognized extrahepatic reservoir [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Recent work by Wang et al. demonstrated that the chemerin receptors GPR1 and CMKLR1 orchestrate lipid storage and suppress lipolysis to sustain ccRCC growth [<xref ref-type="bibr" rid="CR73">73</xref>]. Timothy D. Klasson and his team reported ACSL3-driven exogenous lipid metabolism underpins the clear-cell phenotype and ferroptosis sensitivity of ccRCC [<xref ref-type="bibr" rid="CR74">74</xref>]. Consistently, a Mendelian randomization study indicated that genetically elevated cholesterol increases kidney cancer risk [<xref ref-type="bibr" rid="CR75">75</xref>]. Collectively, these convergent findings support the hypothesis that HCV-induced lipid-metabolic dysregulation may be involved in renal carcinogenesis. Future investigations should delineate the precise molecular mechanisms by which HCV perturbs renal lipid homeostasis and oncogenesis.</p><p id="Par37">We explored the potential mediators identified through mediation analysis (e.g., CD38, CD25, aspartylphenylalanine) and colocalization analysis (e.g., <italic toggle="yes">IRF5</italic>, <italic toggle="yes">SLC22A7</italic>, <italic toggle="yes">OCEL1</italic>). Although current research has not explored these two sets of findings, they may be biologically interconnected. For instance, CD38 and CD25 are immune cell surface molecules that may mediate the relationship between HCV infection and extrahepatic cancers by influencing immune responses [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. <italic toggle="yes">IRF5</italic>, as a key regulator of interferon, may play a significant role in immune signaling and interact functionally with CD38 and CD25 [<xref ref-type="bibr" rid="CR65">65</xref>]. Additionally, metabolite aspartylphenylalanine may affect cancer development by influencing the cellular metabolic environment, while <italic toggle="yes">SLC22A7</italic>, as a transporter protein, may be involved in the transport and metabolism of metabolites [<xref ref-type="bibr" rid="CR78">78</xref>]. These findings suggest that HCV infection may influence the development of extrahepatic cancers through multiple biological pathways, including immune responses and metabolic pathways. Future studies could further explore these potential biological mechanisms to uncover the complex relationship between HCV infection and extrahepatic cancers.</p><p id="Par38">Next, we established a three-HSGs prognostic model for kidney cancer using data from TCGA-KICH, TCGA-KIRC and TCGA-KIRP. Our risk score, which was derived from the expression levels of the three HSGs, including <italic toggle="yes">GTSE1</italic>, <italic toggle="yes">TOLLIP</italic> and <italic toggle="yes">SPOCD1</italic>, demonstrated strong predictive accuracy for the prognosis of individuals with kidney cancer acting as an independent prognostic factor. An increasing number of studies have explored the role of the three genes on cancers, especially on kidney cancer. The <italic toggle="yes">GTSE1</italic> gene encodes the G2 and S phase-expressed-1 protein, which is vital for ensuring proper chromosomal movement and spindle integrity during the process of mitosis [<xref ref-type="bibr" rid="CR79">79</xref>]. <italic toggle="yes">GTSE1</italic> was overexpressed in ccRCC tissue samples, where it can facilitate tumor growth and metastasis by suppressing the expression of <italic toggle="yes">KLF4</italic> [<xref ref-type="bibr" rid="CR80">80</xref>]. Pu Lei et al. found that <italic toggle="yes">GTSE1</italic> was associated with immune cell infiltration and worse prognosis for ccRCC based on bioinformatics analysis [<xref ref-type="bibr" rid="CR81">81</xref>]. The <italic toggle="yes">TOLLIP</italic> gene encode an ubiquitin-binding protein that interacts with several Toll-like receptor (TLR) signaling cascade components, which is responsible for IL-1 receptor trafficking and the turnover of IL-1 receptor -associated kinase [<xref ref-type="bibr" rid="CR82">82</xref>]. At present, there is still controversy about whether <italic toggle="yes">TOLLIP</italic> plays an oncogenic role or tumor suppressor role. The expression of <italic toggle="yes">TOLLIP</italic> was found downregulated in gastric adenocarcinoma in comparison to normal mucosa, which implied that <italic toggle="yes">TOLLIP</italic> may inhibit the progression of gastric cancer [<xref ref-type="bibr" rid="CR83">83</xref>]. On the contrast, Christina Begka et al. reported that <italic toggle="yes">TOLLIP</italic>-deficient mice were unable to produce an effective chronic inflammatory response, thus resulting in reduced tumor risk [<xref ref-type="bibr" rid="CR84">84</xref>]. In our study, <italic toggle="yes">TOLLIP</italic> was identified as a protective factor for the prognosis of kidney cancer. However, Adam Kowalewski et al. has reported that <italic toggle="yes">TOLLIP</italic> protein was significantly correlated with a lower overall survival rate in RCC [<xref ref-type="bibr" rid="CR85">85</xref>]. It was important to note that we focused on the mRNA levels, while Adam Kowalewski et al. were studying at protein levels. Further research is needed to clarify TOLLIP&#8217;s role in cancer development. <italic toggle="yes">SPOCD1</italic>, encoding the spen paralogue and orthologue C-terminal domain containing 1 and as a member of the transcription factor S-II family, is an essential executor of mammalian piRNA-directed DNA methylation [<xref ref-type="bibr" rid="CR86">86</xref>]. Meng Zhu et al. found that genetic variants on <italic toggle="yes">SPOCD1</italic> were associated with risk of gastric cancer, and knockdown of <italic toggle="yes">SPOCD1</italic> could inhibit the proliferation and invasion of gastric cancer in vitro and in vivo [<xref ref-type="bibr" rid="CR87">87</xref>]. For gliomas, <italic toggle="yes">SPOCD1</italic> was reported to promote the proliferation and metastasis by up-regulating <italic toggle="yes">PTX3</italic> [<xref ref-type="bibr" rid="CR88">88</xref>]. At present, the mechanism of <italic toggle="yes">SPOCDI</italic> in the occurrence and development of kidney cancer has not been deeply explored.</p><p id="Par39">Finally, we used the GRS analysis to validate the causal association between HCV infection and kidney cancer using data in the UK Biobank database, and the results showed the same direction and magnitude of effect consistent with those estimated in the two-sample MR and MVMR. In recent years, GRS has been used as a tool for causal inference [<xref ref-type="bibr" rid="CR89">89</xref>]. GRS can evaluate the cumulative effects of multiple SNPs to increase statistical power and reduce costs in the process of causal inference. Our results showed that an increase in weighted GRS score for HCV infection was significantly associated with an increased prevalence of kidney cancer after adjusting for the other seven covariates.</p><p id="Par40">Our study was subject to several limitations. Firstly, the orignial GWAS data on HCV infection and certain cancers have a limited number of cases, which may introduce bias. Although our sensitivity analyses support the robustness and stability of our MR estimates, further large scale association studies are warranted. Secondly, since our study was only involved in European populations, the conclusions may not be applicable to populations of other ancestry. Thirdly, the mediators we found still need more basic experimental data and clinical studies to corroborate. Finally, it is necessary to confirm the association of HCV infection and extrahepatic cancers using basic experiments in vivo and in vitro.</p></sec><sec id="Sec13"><title>Conclusion</title><p id="Par41">In summary, we conducted a thorough investigation about the causal effects of HCV infection on extrahepatic cancers. Our findings indicate that HCV infection may be a risk factor for kidney cancer. CD38, DNA-3-methyladenine glycosylase, pappalysin 1, aspartylphenylalanine, CD25 on naive-mature B cell and SSC-A on HLA DR&#8201;+&#8201;CD4&#8201;+&#8201;T cell were potential intermediate variables linking HCV infection with kidney cancer. Notably, <italic toggle="yes">IRF5</italic> is a central hub gene linking HCV infection to kidney cancer. Additionally, a novel model with three-hub HSGs can effectively predict overall survival in patients with kidney cancer. Our study offers new insights into the causal relationship between HCV infection and extrahepatic cancers, highlighting the need for further basic and clinical research to elucidate this connection.</p></sec><sec id="Sec14" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="13027_2025_693_MOESM1_ESM.rar" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>LC and JL designed the study and guided work. QW, TY and YW performed data analysis. QW, HR, XX and JL wrote the manuscript and helped with validation. All authors interpreted the results and read and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (Grant/Award Numbers: 82272418, 81903394).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par42">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par43">All authors consent for publication.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par44">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>MV</given-names></name><name name-style="western"><surname>King</surname><given-names>LY</given-names></name><name name-style="western"><surname>Chung</surname><given-names>RT</given-names></name></person-group><article-title>Hepatitis C virus-associated cancer</article-title><source>Annu Rev Pathol</source><year>2015</year><volume>10</volume><fpage>345</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">25387053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathol-012414-040323</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Lin MV, King LY, Chung RT. Hepatitis C virus-associated cancer. Annu Rev Pathol. 2015;10:345&#8211;70.<pub-id pub-id-type="pmid">25387053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathol-012414-040323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Virzi A, Roca Suarez AA, Baumert TF, Lupberger J. Oncogenic signaling induced by HCV infection. Viruses. 2018;10(10).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v10100538</pub-id><pub-id pub-id-type="pmcid">PMC6212953</pub-id><pub-id pub-id-type="pmid">30279347</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Stroffolini T, Stroffolini G. Prevalence and modes of transmission of hepatitis C virus infection: A historical worldwide review. Viruses. 2024;16(7).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v16071115</pub-id><pub-id pub-id-type="pmcid">PMC11281430</pub-id><pub-id pub-id-type="pmid">39066277</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burki</surname><given-names>T</given-names></name></person-group><article-title>WHO&#8217;s 2024 global hepatitis report</article-title><source>Lancet Infect Dis</source><year>2024</year><volume>24</volume><issue>6</issue><fpage>e362</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">38795729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(24)00307-4</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Burki T. WHO&#8217;s 2024 global hepatitis report. Lancet Infect Dis. 2024;24(6):e362&#8211;3.<pub-id pub-id-type="pmid">38795729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(24)00307-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209&#8211;49.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>JP</given-names></name><name name-style="western"><surname>LoConte</surname><given-names>NK</given-names></name><name name-style="western"><surname>Rice</surname><given-names>JP</given-names></name><name name-style="western"><surname>Foxhall</surname><given-names>LE</given-names></name><name name-style="western"><surname>Sturgis</surname><given-names>EM</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Oncologic implications of chronic hepatitis C virus infection</article-title><source>J Oncol Pract</source><year>2019</year><volume>15</volume><issue>12</issue><fpage>629</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">31825756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JOP.19.00370</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, et al. Oncologic implications of chronic hepatitis C virus infection. J Oncol Pract. 2019;15(12):629&#8211;37.<pub-id pub-id-type="pmid">31825756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JOP.19.00370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyberg</surname><given-names>AH</given-names></name><name name-style="western"><surname>Chung</surname><given-names>JW</given-names></name><name name-style="western"><surname>Shi</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cheetham</surname><given-names>TC</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>KM</given-names></name><name name-style="western"><surname>Haque</surname><given-names>R</given-names></name><etal/></person-group><article-title>O058: increased cancer rates in patients with chronic hepatitis C: an analysis of the cancer registry in a large U.S. Health maintenance organization</article-title><source>J Hepatol</source><year>2015</year><volume>62</volume><fpage>S220</fpage></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Nyberg AH, Chung JW, Shi JM, Cheetham TC, Chiang KM, Haque R, et al. O058: increased cancer rates in patients with chronic hepatitis C: an analysis of the cancer registry in a large U.S. Health maintenance organization. J Hepatol. 2015;62:S220.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maliko</surname><given-names>M</given-names></name><name name-style="western"><surname>Su</surname><given-names>FH</given-names></name><name name-style="western"><surname>Kamiza</surname><given-names>AB</given-names></name><name name-style="western"><surname>Su</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>CC</given-names></name></person-group><article-title>The association between hepatic viral infections and cancers: a cross-sectional study in the Taiwan adult population</article-title><source>Clin Exp Med</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>20</fpage><pub-id pub-id-type="pmid">38279980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-023-01292-x</pub-id><pub-id pub-id-type="pmcid">PMC10821961</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Maliko M, Su FH, Kamiza AB, Su MJ, Yeh CC. The association between hepatic viral infections and cancers: a cross-sectional study in the Taiwan adult population. Clin Exp Med. 2024;24(1):20.<pub-id pub-id-type="pmid">38279980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-023-01292-x</pub-id><pub-id pub-id-type="pmcid">PMC10821961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pol</surname><given-names>S</given-names></name><name name-style="western"><surname>Vallet-Pichard</surname><given-names>A</given-names></name><name name-style="western"><surname>Hermine</surname><given-names>O</given-names></name></person-group><article-title>Extrahepatic cancers and chronic HCV infection</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2018</year><volume>15</volume><issue>5</issue><fpage>283</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">29339810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrgastro.2017.172</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Pol S, Vallet-Pichard A, Hermine O. Extrahepatic cancers and chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2018;15(5):283&#8211;90.<pub-id pub-id-type="pmid">29339810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrgastro.2017.172</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Chen YFF, Chen As Fau - Hao A-S, Hao F, Fau - Zhao F. X-P, Zhao Xp Fau - Gu C-H, Gu Ch Fau - Zhao L-B, Zhao Lb Fau - Yang D-L, Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. (2219&#8211;2840 (Electronic)).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v6.i6.805</pub-id><pub-id pub-id-type="pmcid">PMC4728266</pub-id><pub-id pub-id-type="pmid">11819700</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zampino</surname><given-names>R</given-names></name><name name-style="western"><surname>Marrone</surname><given-names>A</given-names></name><name name-style="western"><surname>Restivo</surname><given-names>L</given-names></name><name name-style="western"><surname>Guerrera</surname><given-names>B</given-names></name><name name-style="western"><surname>Sellitto</surname><given-names>A</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations</article-title><source>World J Hepatol</source><year>2013</year><volume>5</volume><issue>10</issue><fpage>528</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">24179612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4254/wjh.v5.i10.528</pub-id><pub-id pub-id-type="pmcid">PMC3812455</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5(10):528&#8211;40.<pub-id pub-id-type="pmid">24179612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4254/wjh.v5.i10.528</pub-id><pub-id pub-id-type="pmcid">PMC3812455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bataller</surname><given-names>R</given-names></name><name name-style="western"><surname>Paik</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Lindquist</surname><given-names>JN</given-names></name><name name-style="western"><surname>Lemasters</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>DA</given-names></name></person-group><article-title>Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><issue>2</issue><fpage>529</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">14762790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2003.11.018</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bataller R, Paik Y-H, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004;126(2):529&#8211;40.<pub-id pub-id-type="pmid">14762790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2003.11.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalor</surname><given-names>PF</given-names></name><name name-style="western"><surname>Shields</surname><given-names>P</given-names></name><name name-style="western"><surname>Grant</surname><given-names>A</given-names></name><name name-style="western"><surname>Adams</surname><given-names>DH</given-names></name></person-group><article-title>Recruitment of lymphocytes to the human liver</article-title><source>Immunol Cell Biol</source><year>2002</year><volume>80</volume><issue>1</issue><fpage>52</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">11869363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1440-1711.2002.01062.x</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lalor PF, Shields P, Grant A, Adams DH. Recruitment of lymphocytes to the human liver. Immunol Cell Biol. 2002;80(1):52&#8211;64.<pub-id pub-id-type="pmid">11869363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1440-1711.2002.01062.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafo MR et al. Mendelian randomization. Nat Rev Methods Primers. 2022;2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43586-021-00092-5</pub-id><pub-id pub-id-type="pmcid">PMC7614635</pub-id><pub-id pub-id-type="pmid">37325194</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Hemani</surname><given-names>G</given-names></name></person-group><article-title>Mendelian randomization: genetic anchors for causal inference in epidemiological studies</article-title><source>Hum Mol Genet</source><year>2014</year><volume>23</volume><issue>R1</issue><fpage>R89</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">25064373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddu328</pub-id><pub-id pub-id-type="pmcid">PMC4170722</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89&#8211;98.<pub-id pub-id-type="pmid">25064373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddu328</pub-id><pub-id pub-id-type="pmcid">PMC4170722</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>A generalized linear mixed model association tool for biobank-scale data</article-title><source>Nat Genet</source><year>2021</year><volume>53</volume><issue>11</issue><fpage>1616</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">34737426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00954-4</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 2021;53(11):1616&#8211;21.<pub-id pub-id-type="pmid">34737426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00954-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Mendelian randomization and transcriptomic analysis reveal an inverse causal relationship between alzheimer&#8217;s disease and cancer</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>527</fpage><pub-id pub-id-type="pmid">37542274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04357-3</pub-id><pub-id pub-id-type="pmcid">PMC10403895</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Dong Z, Xu M, Sun X, Wang X. Mendelian randomization and transcriptomic analysis reveal an inverse causal relationship between alzheimer&#8217;s disease and cancer. J Transl Med. 2023;21(1):527.<pub-id pub-id-type="pmid">37542274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04357-3</pub-id><pub-id pub-id-type="pmcid">PMC10403895</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salamone</surname><given-names>D</given-names></name><name name-style="western"><surname>Rivellese</surname><given-names>AA</given-names></name><name name-style="western"><surname>Vetrani</surname><given-names>C</given-names></name></person-group><article-title>The relationship between gut microbiota, short-chain fatty acids and type 2 diabetes mellitus: the possible role of dietary fibre</article-title><source>Acta Diabetol</source><year>2021</year><volume>58</volume><issue>9</issue><fpage>1131</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">33970303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00592-021-01727-5</pub-id><pub-id pub-id-type="pmcid">PMC8316221</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Salamone D, Rivellese AA, Vetrani C. The relationship between gut microbiota, short-chain fatty acids and type 2 diabetes mellitus: the possible role of dietary fibre. Acta Diabetol. 2021;58(9):1131&#8211;8.<pub-id pub-id-type="pmid">33970303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00592-021-01727-5</pub-id><pub-id pub-id-type="pmcid">PMC8316221</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mendelian randomization analyses support causal relationships between blood metabolites and the gut Microbiome</article-title><source>Nat Genet</source><year>2022</year><volume>54</volume><issue>1</issue><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">34980918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00968-y</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Liu X, Tong X, Zou Y, Lin X, Zhao H, Tian L, et al. Mendelian randomization analyses support causal relationships between blood metabolites and the gut Microbiome. Nat Genet. 2022;54(1):52&#8211;61.<pub-id pub-id-type="pmid">34980918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00968-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakaue</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanai</surname><given-names>M</given-names></name><name name-style="western"><surname>Karjalainen</surname><given-names>J</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Kurki</surname><given-names>M</given-names></name><name name-style="western"><surname>Matoba</surname><given-names>N</given-names></name><etal/></person-group><article-title>Trans-biobank analysis with 676,000 individuals elucidates the association of polygenic risk scores of complex traits with human lifespan</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>4</issue><fpage>542</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32251405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0785-8</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Sakaue S, Kanai M, Karjalainen J, Akiyama M, Kurki M, Matoba N, et al. Trans-biobank analysis with 676,000 individuals elucidates the association of polygenic risk scores of complex traits with human lifespan. Nat Med. 2020;26(4):542&#8211;8.<pub-id pub-id-type="pmid">32251405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0785-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greco</surname><given-names>MFD</given-names></name><name name-style="western"><surname>Minelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>NA</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>JR</given-names></name></person-group><article-title>Detecting Pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome</article-title><source>Stat Med</source><year>2015</year><volume>34</volume><issue>21</issue><fpage>2926</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">25950993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.6522</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Greco MFD, Minelli C, Sheehan NA, Thompson JR. Detecting Pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34(21):2926&#8211;40.<pub-id pub-id-type="pmid">25950993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.6522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name></person-group><article-title>Mendelian randomization with invalid instruments: effect Estimation and bias detection through Egger regression</article-title><source>Int J Epidemiol</source><year>2015</year><volume>44</volume><issue>2</issue><fpage>512</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">26050253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyv080</pub-id><pub-id pub-id-type="pmcid">PMC4469799</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect Estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512&#8211;25.<pub-id pub-id-type="pmid">26050253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyv080</pub-id><pub-id pub-id-type="pmcid">PMC4469799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbanck</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Neale</surname><given-names>B</given-names></name><name name-style="western"><surname>Do</surname><given-names>R</given-names></name></person-group><article-title>Detection of widespread horizontal Pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases</article-title><source>Nat Genet</source><year>2018</year><volume>50</volume><issue>5</issue><fpage>693</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">29686387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0099-7</pub-id><pub-id pub-id-type="pmcid">PMC6083837</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal Pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693&#8211;8.<pub-id pub-id-type="pmid">29686387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0099-7</pub-id><pub-id pub-id-type="pmcid">PMC6083837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>NM</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>MV</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><article-title>Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians</article-title><source>BMJ</source><year>2018</year><volume>362</volume><fpage>k601</fpage><pub-id pub-id-type="pmid">30002074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k601</pub-id><pub-id pub-id-type="pmcid">PMC6041728</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.<pub-id pub-id-type="pmid">30002074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k601</pub-id><pub-id pub-id-type="pmcid">PMC6041728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>D</given-names></name><name name-style="western"><surname>Michita</surname><given-names>RT</given-names></name><name name-style="western"><surname>Beria</surname><given-names>JU</given-names></name><name name-style="western"><surname>Tietzmann</surname><given-names>DC</given-names></name><name name-style="western"><surname>Stein</surname><given-names>AT</given-names></name><name name-style="western"><surname>Lunge</surname><given-names>VR</given-names></name></person-group><article-title>Alcohol misuse and illicit drug use are associated with HCV/HIV co-infection</article-title><source>Epidemiol Infect</source><year>2014</year><volume>142</volume><issue>12</issue><fpage>2616</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">24512701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0950268814000041</pub-id><pub-id pub-id-type="pmcid">PMC9151251</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Simon D, Michita RT, Beria JU, Tietzmann DC, Stein AT, Lunge VR. Alcohol misuse and illicit drug use are associated with HCV/HIV co-infection. Epidemiol Infect. 2014;142(12):2616&#8211;23.<pub-id pub-id-type="pmid">24512701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0950268814000041</pub-id><pub-id pub-id-type="pmcid">PMC9151251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Sanderson E. Multivariable Mendelian randomization and mediation. Cold Spring Harb Perspect Med. 2021;11(2).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a038984</pub-id><pub-id pub-id-type="pmcid">PMC7849347</pub-id><pub-id pub-id-type="pmid">32341063</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>GRB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Jang</surname><given-names>S-K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Genetic diversity fuels gene discovery for tobacco and alcohol use</article-title><source>Nature</source><year>2022</year><volume>612</volume><issue>7941</issue><fpage>720</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">36477530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05477-4</pub-id><pub-id pub-id-type="pmcid">PMC9771818</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Saunders GRB, Wang X, Chen F, Jang S-K, Liu M, Wang C, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature. 2022;612(7941):720&#8211;4.<pub-id pub-id-type="pmid">36477530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05477-4</pub-id><pub-id pub-id-type="pmcid">PMC9771818</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Fauman</surname><given-names>EB</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>A-K</given-names></name><name name-style="western"><surname>Krumsiek</surname><given-names>J</given-names></name><name name-style="western"><surname>Santos</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group><article-title>An atlas of genetic influences on human blood metabolites</article-title><source>Nat Genet</source><year>2014</year><volume>46</volume><issue>6</issue><fpage>543</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">24816252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2982</pub-id><pub-id pub-id-type="pmcid">PMC4064254</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Shin S-Y, Fauman EB, Petersen A-K, Krumsiek J, Santos R, Huang J, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543&#8211;50.<pub-id pub-id-type="pmid">24816252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2982</pub-id><pub-id pub-id-type="pmcid">PMC4064254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>BB</given-names></name><name name-style="western"><surname>Maranville</surname><given-names>JC</given-names></name><name name-style="western"><surname>Peters</surname><given-names>JE</given-names></name><name name-style="western"><surname>Stacey</surname><given-names>D</given-names></name><name name-style="western"><surname>Staley</surname><given-names>JR</given-names></name><name name-style="western"><surname>Blackshaw</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genomic atlas of the human plasma proteome</article-title><source>Nature</source><year>2018</year><volume>558</volume><issue>7708</issue><fpage>73</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">29875488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0175-2</pub-id><pub-id pub-id-type="pmcid">PMC6697541</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73&#8211;9.<pub-id pub-id-type="pmid">29875488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0175-2</pub-id><pub-id pub-id-type="pmcid">PMC6697541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folkersen</surname><given-names>L</given-names></name><name name-style="western"><surname>Fauman</surname><given-names>E</given-names></name><name name-style="western"><surname>Sabater-Lleal</surname><given-names>M</given-names></name><name name-style="western"><surname>Strawbridge</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Fr&#229;nberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Sennblad</surname><given-names>B</given-names></name><etal/></person-group><article-title>Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease</article-title><source>PLoS Genet</source><year>2017</year><volume>13</volume><issue>4</issue><fpage>e1006706</fpage><pub-id pub-id-type="pmid">28369058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1006706</pub-id><pub-id pub-id-type="pmcid">PMC5393901</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge RJ, Fr&#229;nberg M, Sennblad B, et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet. 2017;13(4):e1006706.<pub-id pub-id-type="pmid">28369058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1006706</pub-id><pub-id pub-id-type="pmcid">PMC5393901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orr&#249;</surname><given-names>V</given-names></name><name name-style="western"><surname>Steri</surname><given-names>M</given-names></name><name name-style="western"><surname>Sidore</surname><given-names>C</given-names></name><name name-style="western"><surname>Marongiu</surname><given-names>M</given-names></name><name name-style="western"><surname>Serra</surname><given-names>V</given-names></name><name name-style="western"><surname>Olla</surname><given-names>S</given-names></name><etal/></person-group><article-title>Complex genetic signatures in immune cells underlie autoimmunity and inform therapy</article-title><source>Nat Genet</source><year>2020</year><volume>52</volume><issue>10</issue><fpage>1036</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">32929287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-0684-4</pub-id><pub-id pub-id-type="pmcid">PMC8517961</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Orr&#249; V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet. 2020;52(10):1036&#8211;45.<pub-id pub-id-type="pmid">32929287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-0684-4</pub-id><pub-id pub-id-type="pmcid">PMC8517961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>AR</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>E</given-names></name><name name-style="western"><surname>Hammerton</surname><given-names>G</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>RC</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Heron</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mendelian randomisation for mediation analysis: current methods and challenges for implementation</article-title><source>Eur J Epidemiol</source><year>2021</year><volume>36</volume><issue>5</issue><fpage>465</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">33961203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-021-00757-1</pub-id><pub-id pub-id-type="pmcid">PMC8159796</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36(5):465&#8211;78.<pub-id pub-id-type="pmid">33961203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-021-00757-1</pub-id><pub-id pub-id-type="pmcid">PMC8159796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>CK</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Sherlock: detecting gene-disease associations by matching patterns of expression QTL and GWAS</article-title><source>Am J Hum Genet</source><year>2013</year><volume>92</volume><issue>5</issue><fpage>667</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">23643380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2013.03.022</pub-id><pub-id pub-id-type="pmcid">PMC3644637</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">He X, Fuller CK, Song Y, Meng Q, Zhang B, Yang X, et al. Sherlock: detecting gene-disease associations by matching patterns of expression QTL and GWAS. Am J Hum Genet. 2013;92(5):667&#8211;80.<pub-id pub-id-type="pmid">23643380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2013.03.022</pub-id><pub-id pub-id-type="pmcid">PMC3644637</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Ibanez L, Heitsch L, Carrera C, Farias FHG, Del Aguila JL, Dhar R, et al. Multi-ancestry GWAS reveals excitotoxicity associated with outcome after ischaemic stroke. Brain. 2022;145(7):2394&#8211;406.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac080</pub-id><pub-id pub-id-type="pmcid">PMC9890452</pub-id><pub-id pub-id-type="pmid">35213696</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Pache</surname><given-names>L</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M</given-names></name><name name-style="western"><surname>Khodabakhshi</surname><given-names>AH</given-names></name><name name-style="western"><surname>Tanaseichuk</surname><given-names>O</given-names></name><etal/></person-group><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>1523</fpage><pub-id pub-id-type="pmid">30944313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-09234-6</pub-id><pub-id pub-id-type="pmcid">PMC6447622</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.<pub-id pub-id-type="pmid">30944313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-09234-6</pub-id><pub-id pub-id-type="pmcid">PMC6447622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>TCGAplot: an R package for integrative pan-cancer analysis and visualization of TCGA multi-omics data</article-title><source>BMC Bioinformatics</source><year>2023</year><volume>24</volume><issue>1</issue><fpage>483</fpage><pub-id pub-id-type="pmid">38105215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12859-023-05615-3</pub-id><pub-id pub-id-type="pmcid">PMC10726608</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Liao C, Wang X. TCGAplot: an R package for integrative pan-cancer analysis and visualization of TCGA multi-omics data. BMC Bioinformatics. 2023;24(1):483.<pub-id pub-id-type="pmid">38105215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12859-023-05615-3</pub-id><pub-id pub-id-type="pmcid">PMC10726608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G</given-names></name><name name-style="western"><surname>Shou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development of a four-gene prognostic model for clear cell renal cell carcinoma based on transcriptome analysis</article-title><source>Genomics</source><year>2021</year><volume>113</volume><issue>4</issue><fpage>1816</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">33838279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygeno.2021.04.005</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Liu Y, Huang Z, Cheng G, Shou Y, Xu J, Liu D, et al. Development of a four-gene prognostic model for clear cell renal cell carcinoma based on transcriptome analysis. Genomics. 2021;113(4):1816&#8211;27.<pub-id pub-id-type="pmid">33838279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygeno.2021.04.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groeneveld</surname><given-names>CS</given-names></name><name name-style="western"><surname>Chagas</surname><given-names>VS</given-names></name><name name-style="western"><surname>Jones</surname><given-names>SJM</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>AG</given-names></name><name name-style="western"><surname>Ponder</surname><given-names>BAJ</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>KB</given-names></name><etal/></person-group><article-title>RTNsurvival: an r/bioconductor package for regulatory network survival analysis</article-title><source>Bioinformatics</source><year>2019</year><volume>35</volume><issue>21</issue><fpage>4488</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30923832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btz229</pub-id><pub-id pub-id-type="pmcid">PMC6821288</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Groeneveld CS, Chagas VS, Jones SJM, Robertson AG, Ponder BAJ, Meyer KB, et al. RTNsurvival: an r/bioconductor package for regulatory network survival analysis. Bioinformatics. 2019;35(21):4488&#8211;9.<pub-id pub-id-type="pmid">30923832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btz229</pub-id><pub-id pub-id-type="pmcid">PMC6821288</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><article-title>The Lasso method for variable selection in the Cox model</article-title><source>Stat Med</source><year>1997</year><volume>16</volume><issue>4</issue><fpage>385</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">9044528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-0258(19970228)16:4&lt;385::aid-sim380&gt;3.0.co;2-3</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Tibshirani R. The Lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385&#8211;95.<pub-id pub-id-type="pmid">9044528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-0258(19970228)16:4&lt;385::aid-sim380&gt;3.0.co;2-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igo</surname><given-names>RP</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Kinzy</surname><given-names>TG</given-names></name><name name-style="western"><surname>Cooke Bailey</surname><given-names>JN</given-names></name></person-group><article-title>Genetic risk scores</article-title><source>Curr Protoc Hum Genet</source><year>2019</year><volume>104</volume><issue>1</issue><fpage>e95</fpage><pub-id pub-id-type="pmid">31765077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cphg.95</pub-id><pub-id pub-id-type="pmcid">PMC6941594</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Igo RP Jr., Kinzy TG, Cooke Bailey JN. Genetic risk scores. Curr Protoc Hum Genet. 2019;104(1):e95.<pub-id pub-id-type="pmid">31765077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cphg.95</pub-id><pub-id pub-id-type="pmcid">PMC6941594</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name><name name-style="western"><surname>Tapper</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Collins</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamady</surname><given-names>ZZR</given-names></name></person-group><article-title>Predicting pancreatic cancer in the UK biobank cohort using polygenic risk scores and diabetes mellitus</article-title><source>Gastroenterology</source><year>2022</year><volume>162</volume><issue>6</issue><fpage>1665</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">35065983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2022.01.016</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Sharma S, Tapper WJ, Collins A, Hamady ZZR. Predicting pancreatic cancer in the UK biobank cohort using polygenic risk scores and diabetes mellitus. Gastroenterology. 2022;162(6):1665&#8211;74. e2.<pub-id pub-id-type="pmid">35065983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2022.01.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collister</surname><given-names>JA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>L</given-names></name></person-group><article-title>Calculating polygenic risk scores (PRS) in UK biobank: A practical guide for epidemiologists</article-title><source>Front Genet</source><year>2022</year><volume>13</volume><fpage>818574</fpage><pub-id pub-id-type="pmid">35251129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.818574</pub-id><pub-id pub-id-type="pmcid">PMC8894758</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Collister JA, Liu X, Clifton L. Calculating polygenic risk scores (PRS) in UK biobank: A practical guide for epidemiologists. Front Genet. 2022;13:818574.<pub-id pub-id-type="pmid">35251129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.818574</pub-id><pub-id pub-id-type="pmcid">PMC8894758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bycroft</surname><given-names>C</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>C</given-names></name><name name-style="western"><surname>Petkova</surname><given-names>D</given-names></name><name name-style="western"><surname>Band</surname><given-names>G</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>LT</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>K</given-names></name><etal/></person-group><article-title>The UK biobank resource with deep phenotyping and genomic data</article-title><source>Nature</source><year>2018</year><volume>562</volume><issue>7726</issue><fpage>203</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30305743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0579-z</pub-id><pub-id pub-id-type="pmcid">PMC6786975</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203&#8211;9.<pub-id pub-id-type="pmid">30305743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0579-z</pub-id><pub-id pub-id-type="pmcid">PMC6786975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurki</surname><given-names>MI</given-names></name><name name-style="western"><surname>Karjalainen</surname><given-names>J</given-names></name><name name-style="western"><surname>Palta</surname><given-names>P</given-names></name><name name-style="western"><surname>Sipil&#228;</surname><given-names>TP</given-names></name><name name-style="western"><surname>Kristiansson</surname><given-names>K</given-names></name><name name-style="western"><surname>Donner</surname><given-names>KM</given-names></name><etal/></person-group><article-title>FinnGen provides genetic insights from a well-phenotyped isolated population</article-title><source>Nature</source><year>2023</year><volume>613</volume><issue>7944</issue><fpage>508</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">36653562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05473-8</pub-id><pub-id pub-id-type="pmcid">PMC9849126</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kurki MI, Karjalainen J, Palta P, Sipil&#228; TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508&#8211;18.<pub-id pub-id-type="pmid">36653562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05473-8</pub-id><pub-id pub-id-type="pmcid">PMC9849126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>McKay</surname><given-names>JD</given-names></name><name name-style="western"><surname>Rafnar</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Timofeeva</surname><given-names>MN</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>P</given-names></name><etal/></person-group><article-title>Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer</article-title><source>Nat Genet</source><year>2014</year><volume>46</volume><issue>7</issue><fpage>736</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">24880342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3002</pub-id><pub-id pub-id-type="pmcid">PMC4074058</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736&#8211;41.<pub-id pub-id-type="pmid">24880342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3002</pub-id><pub-id pub-id-type="pmcid">PMC4074058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michailidou</surname><given-names>K</given-names></name><name name-style="western"><surname>Lindstr&#246;m</surname><given-names>S</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>J</given-names></name><name name-style="western"><surname>Beesley</surname><given-names>J</given-names></name><name name-style="western"><surname>Hui</surname><given-names>S</given-names></name><name name-style="western"><surname>Kar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association analysis identifies 65 new breast cancer risk loci</article-title><source>Nature</source><year>2017</year><volume>551</volume><issue>7678</issue><fpage>92</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">29059683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature24284</pub-id><pub-id pub-id-type="pmcid">PMC5798588</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Michailidou K, Lindstr&#246;m S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678):92&#8211;4.<pub-id pub-id-type="pmid">29059683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature24284</pub-id><pub-id pub-id-type="pmcid">PMC5798588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phelan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kuchenbaecker</surname><given-names>KB</given-names></name><name name-style="western"><surname>Tyrer</surname><given-names>JP</given-names></name><name name-style="western"><surname>Kar</surname><given-names>SP</given-names></name><name name-style="western"><surname>Lawrenson</surname><given-names>K</given-names></name><name name-style="western"><surname>Winham</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer</article-title><source>Nat Genet</source><year>2017</year><volume>49</volume><issue>5</issue><fpage>680</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">28346442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3826</pub-id><pub-id pub-id-type="pmcid">PMC5612337</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49(5):680&#8211;91.<pub-id pub-id-type="pmid">28346442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3826</pub-id><pub-id pub-id-type="pmcid">PMC5612337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schumacher</surname><given-names>FR</given-names></name><name name-style="western"><surname>Al Olama</surname><given-names>AA</given-names></name><name name-style="western"><surname>Berndt</surname><given-names>SI</given-names></name><name name-style="western"><surname>Benlloch</surname><given-names>S</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>M</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci</article-title><source>Nat Genet</source><year>2018</year><volume>50</volume><issue>7</issue><fpage>928</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">29892016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0142-8</pub-id><pub-id pub-id-type="pmcid">PMC6568012</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50(7):928&#8211;36.<pub-id pub-id-type="pmid">29892016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0142-8</pub-id><pub-id pub-id-type="pmcid">PMC6568012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lappalainen</surname><given-names>T</given-names></name><name name-style="western"><surname>MacArthur</surname><given-names>DG</given-names></name></person-group><article-title>From variant to function in human disease genetics</article-title><source>Sci (New York NY)</source><year>2021</year><volume>373</volume><issue>6562</issue><fpage>1464</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abi8207</pub-id><pub-id pub-id-type="pmid">34554789</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Lappalainen T, MacArthur DG. From variant to function in human disease genetics. Sci (New York NY). 2021;373(6562):1464&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abi8207</pub-id><pub-id pub-id-type="pmid">34554789</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Association of hepatitis C infection and risk of kidney cancer: A systematic review and meta-analysis of observational studies</article-title><source>J Viral Hepat</source><year>2021</year><volume>28</volume><issue>2</issue><fpage>226</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">33141502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvh.13434</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Wu D, Hu S, Chen G, Chen L, Liu J, Chen W, et al. Association of hepatitis C infection and risk of kidney cancer: A systematic review and meta-analysis of observational studies. J Viral Hepat. 2021;28(2):226&#8211;35.<pub-id pub-id-type="pmid">33141502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvh.13434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name></person-group><article-title>The association between hepatitis C virus infection and renal cell cancer, prostate cancer, and bladder cancer: a systematic review and meta-analysis</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>10833</fpage><pub-id pub-id-type="pmid">34035396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-90404-2</pub-id><pub-id pub-id-type="pmcid">PMC8149817</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Ma Y, Huang Z, Jian Z, Wei X. The association between hepatitis C virus infection and renal cell cancer, prostate cancer, and bladder cancer: a systematic review and meta-analysis. Sci Rep. 2021;11(1):10833.<pub-id pub-id-type="pmid">34035396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-90404-2</pub-id><pub-id pub-id-type="pmcid">PMC8149817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyberg</surname><given-names>AH</given-names></name><name name-style="western"><surname>Sadikova</surname><given-names>E</given-names></name><name name-style="western"><surname>Cheetham</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>KM</given-names></name><name name-style="western"><surname>Shi</surname><given-names>JX</given-names></name><name name-style="western"><surname>Caparosa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Increased cancer rates in patients with chronic hepatitis C</article-title><source>Liver Int</source><year>2020</year><volume>40</volume><issue>3</issue><fpage>685</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">31755208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.14305</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Nyberg AH, Sadikova E, Cheetham C, Chiang KM, Shi JX, Caparosa S, et al. Increased cancer rates in patients with chronic hepatitis C. Liver Int. 2020;40(3):685&#8211;93.<pub-id pub-id-type="pmid">31755208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.14305</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Hepatitis C virus and risk of extrahepatic malignancies: a case-control study</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>19444</fpage><pub-id pub-id-type="pmid">31857595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-55249-w</pub-id><pub-id pub-id-type="pmcid">PMC6923417</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Liu B, Zhang Y, Li J, Zhang W. Hepatitis C virus and risk of extrahepatic malignancies: a case-control study. Sci Rep. 2019;9(1):19444.<pub-id pub-id-type="pmid">31857595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-55249-w</pub-id><pub-id pub-id-type="pmcid">PMC6923417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yan</surname><given-names>HM</given-names></name><name name-style="western"><surname>Liao</surname><given-names>YL</given-names></name></person-group><article-title>No association between hepatitis C virus infection and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies</article-title><source>Front Med (Lausanne)</source><year>2024</year><volume>11</volume><fpage>1327809</fpage><pub-id pub-id-type="pmid">38898936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1327809</pub-id><pub-id pub-id-type="pmcid">PMC11186414</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Chang C, Yan HM, Liao YL. No association between hepatitis C virus infection and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies. Front Med (Lausanne). 2024;11:1327809.<pub-id pub-id-type="pmid">38898936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1327809</pub-id><pub-id pub-id-type="pmcid">PMC11186414</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganz</surname><given-names>M</given-names></name><name name-style="western"><surname>Alessandro</surname><given-names>C</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>M</given-names></name><name name-style="western"><surname>Gejerman</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D</given-names></name><name name-style="western"><surname>Okoye</surname><given-names>F</given-names></name><etal/></person-group><article-title>Exploring the relationship between hepatitis C virus infection and prostate cancer risk: A National health and nutrition examination survey analysis</article-title><source>Cureus</source><year>2024</year><volume>16</volume><issue>2</issue><fpage>e54523</fpage><pub-id pub-id-type="pmid">38516498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.54523</pub-id><pub-id pub-id-type="pmcid">PMC10955788</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Ganz M, Alessandro C, Jacobs M, Gejerman Y, Miller D, Okoye F, et al. Exploring the relationship between hepatitis C virus infection and prostate cancer risk: A National health and nutrition examination survey analysis. Cureus. 2024;16(2):e54523.<pub-id pub-id-type="pmid">38516498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.54523</pub-id><pub-id pub-id-type="pmcid">PMC10955788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koutsoudakis</surname><given-names>G</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Kallis</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartenschlager</surname><given-names>R</given-names></name><name name-style="western"><surname>Pietschmann</surname><given-names>T</given-names></name></person-group><article-title>The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells</article-title><source>J Virol</source><year>2007</year><volume>81</volume><issue>2</issue><fpage>588</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">17079281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01534-06</pub-id><pub-id pub-id-type="pmcid">PMC1797465</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol. 2007;81(2):588&#8211;98.<pub-id pub-id-type="pmid">17079281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01534-06</pub-id><pub-id pub-id-type="pmcid">PMC1797465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pol</surname><given-names>S</given-names></name><name name-style="western"><surname>Parlati</surname><given-names>L</given-names></name><name name-style="western"><surname>Jadoul</surname><given-names>M</given-names></name></person-group><article-title>Hepatitis C virus and the kidney</article-title><source>Nat Rev Nephrol</source><year>2019</year><volume>15</volume><issue>2</issue><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">30455426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-018-0081-8</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019;15(2):73&#8211;86.<pub-id pub-id-type="pmid">30455426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-018-0081-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiwanitkit</surname><given-names>V</given-names></name></person-group><article-title>Renal cell carcinoma and hepatitis C virus infection: is there any cause-outcome relationship?</article-title><source>J Cancer Res Ther</source><year>2011</year><volume>7</volume><issue>2</issue><fpage>226</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21768723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0973-1482.82931</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Wiwanitkit V. Renal cell carcinoma and hepatitis C virus infection: is there any cause-outcome relationship? J Cancer Res Ther. 2011;7(2):226&#8211;7.<pub-id pub-id-type="pmid">21768723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0973-1482.82931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Drake CG, Stein MN. The immunobiology of kidney cancer. J Clin Oncol. 2018 ;36(36):3547&#8211;52.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2018.79.2648</pub-id><pub-id pub-id-type="pmid">30372396</pub-id></mixed-citation></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson Brown</surname><given-names>PM</given-names></name><name name-style="western"><surname>Neuman</surname><given-names>MG</given-names></name></person-group><article-title>Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines</article-title><source>Clin Biochem</source><year>2001</year><volume>34</volume><issue>3</issue><fpage>167</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11408013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0009-9120(01)00210-7</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem. 2001;34(3):167&#8211;71.<pub-id pub-id-type="pmid">11408013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0009-9120(01)00210-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Alanio C, Nicoli F, Sultanik P, Flecken T, Perot B, Duffy D et al. Bystander hyperactivation of preimmune CD8&#8201;+&#8201;T cells in chronic HCV patients. Elife. 2015;4.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.07916</pub-id><pub-id pub-id-type="pmcid">PMC4752008</pub-id><pub-id pub-id-type="pmid">26568315</pub-id></mixed-citation></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shou</surname><given-names>Z</given-names></name></person-group><article-title>Application of CD38 monoclonal antibody in kidney disease</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1382977</fpage><pub-id pub-id-type="pmid">38799465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1382977</pub-id><pub-id pub-id-type="pmcid">PMC11116655</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Chen Z, Xu Q, Shou Z. Application of CD38 monoclonal antibody in kidney disease. Front Immunol. 2024;15:1382977.<pub-id pub-id-type="pmid">38799465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1382977</pub-id><pub-id pub-id-type="pmcid">PMC11116655</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Manik MK, Shi Y, Li S, Zaydman MA, Damaraju N, Eastman S et al. Cyclic ADP ribose isomers: production, chemical structures, and immune signaling. Science. 2022;377(6614).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adc8969</pub-id><pub-id pub-id-type="pmid">36048923</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogan</surname><given-names>KA</given-names></name><name name-style="western"><surname>Chini</surname><given-names>CCS</given-names></name><name name-style="western"><surname>Chini</surname><given-names>EN</given-names></name></person-group><article-title>The Multi-faceted Ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1187</fpage><pub-id pub-id-type="pmid">31214171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01187</pub-id><pub-id pub-id-type="pmcid">PMC6555258</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Hogan KA, Chini CCS, Chini EN. The Multi-faceted Ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10:1187.<pub-id pub-id-type="pmid">31214171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01187</pub-id><pub-id pub-id-type="pmcid">PMC6555258</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>BK</given-names></name><name name-style="western"><surname>Collado</surname><given-names>G</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>BJ</given-names></name></person-group><article-title>Role of interferon regulatory factor 5 (IRF5) in tumor progression: prognostic and therapeutic potential</article-title><source>Biochim Biophys Acta Rev Cancer</source><year>2024</year><volume>1879</volume><issue>1</issue><fpage>189061</fpage><pub-id pub-id-type="pmid">38141865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2023.189061</pub-id><pub-id pub-id-type="pmcid">PMC11977173</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Roberts BK, Collado G, Barnes BJ. Role of interferon regulatory factor 5 (IRF5) in tumor progression: prognostic and therapeutic potential. Biochim Biophys Acta Rev Cancer. 2024;1879(1):189061.<pub-id pub-id-type="pmid">38141865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2023.189061</pub-id><pub-id pub-id-type="pmcid">PMC11977173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xi</surname><given-names>W</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>27</issue><fpage>44186</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">28562332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.17777</pub-id><pub-id pub-id-type="pmcid">PMC5546472</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Bai Q, Liu L, Xia Y, Wang J, Xi W, Qu Y, et al. IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma. Oncotarget. 2017;8(27):44186&#8211;94.<pub-id pub-id-type="pmid">28562332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.17777</pub-id><pub-id pub-id-type="pmcid">PMC5546472</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cytoplasmic localization of IRF5 induces Wnt5a/E-cadherin degradation and promotes gastric cancer cells metastasis</article-title><source>Cancer Gene Ther</source><year>2023</year><volume>30</volume><issue>6</issue><fpage>866</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">36782048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41417-023-00596-0</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Du J, Sun C, Liu J, Wang X, Zhao X, Wang Y, et al. Cytoplasmic localization of IRF5 induces Wnt5a/E-cadherin degradation and promotes gastric cancer cells metastasis. Cancer Gene Ther. 2023;30(6):866&#8211;77.<pub-id pub-id-type="pmid">36782048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41417-023-00596-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Angelo</surname><given-names>A</given-names></name><name name-style="western"><surname>Sobhani</surname><given-names>N</given-names></name><name name-style="western"><surname>Roviello</surname><given-names>G</given-names></name><name name-style="western"><surname>Bagby</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonazza</surname><given-names>D</given-names></name><name name-style="western"><surname>Bottin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><issue>8</issue><fpage>e0219566</fpage><pub-id pub-id-type="pmid">31381571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0219566</pub-id><pub-id pub-id-type="pmcid">PMC6681957</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">D&#8217;Angelo A, Sobhani N, Roviello G, Bagby S, Bonazza D, Bottin C, et al. Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. PLoS ONE. 2019;14(8):e0219566.<pub-id pub-id-type="pmid">31381571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0219566</pub-id><pub-id pub-id-type="pmcid">PMC6681957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthalagu</surname><given-names>N</given-names></name><name name-style="western"><surname>Monteverde</surname><given-names>T</given-names></name><name name-style="western"><surname>Raffo-Iraolagoitia</surname><given-names>X</given-names></name><name name-style="western"><surname>Wiesheu</surname><given-names>R</given-names></name><name name-style="western"><surname>Whyte</surname><given-names>D</given-names></name><name name-style="western"><surname>Hedley</surname><given-names>A</given-names></name><etal/></person-group><article-title>Repression of the type I interferon pathway underlies MYC- and KRAS-Dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma</article-title><source>Cancer Discov</source><year>2020</year><volume>10</volume><issue>6</issue><fpage>872</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">32200350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-19-0620</pub-id><pub-id pub-id-type="pmcid">PMC7611248</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, et al. Repression of the type I interferon pathway underlies MYC- and KRAS-Dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 2020;10(6):872&#8211;87.<pub-id pub-id-type="pmid">32200350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-19-0620</pub-id><pub-id pub-id-type="pmcid">PMC7611248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pimenta</surname><given-names>EM</given-names></name><name name-style="western"><surname>De</surname><given-names>S</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>R</given-names></name><name name-style="western"><surname>Feng</surname><given-names>D</given-names></name><name name-style="western"><surname>Hall</surname><given-names>K</given-names></name><name name-style="western"><surname>Kilic</surname><given-names>S</given-names></name><etal/></person-group><article-title>IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media</article-title><source>Immunol Cell Biol</source><year>2015</year><volume>93</volume><issue>5</issue><fpage>486</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">25533286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2014.110</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Pimenta EM, De S, Weiss R, Feng D, Hall K, Kilic S, et al. IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media. Immunol Cell Biol. 2015;93(5):486&#8211;99.<pub-id pub-id-type="pmid">25533286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2014.110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">Elgretli W, Chen T, Kronfli N, Sebastiani G. Hepatitis C Virus-Lipid interplay: pathogenesis and clinical impact. Biomedicines. 2023;11(2).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11020271</pub-id><pub-id pub-id-type="pmcid">PMC9953247</pub-id><pub-id pub-id-type="pmid">36830808</pub-id></mixed-citation></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heravi</surname><given-names>G</given-names></name><name name-style="western"><surname>Yazdanpanah</surname><given-names>O</given-names></name><name name-style="western"><surname>Podgorski</surname><given-names>I</given-names></name><name name-style="western"><surname>Matherly</surname><given-names>LH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name></person-group><article-title>Lipid metabolism reprogramming in renal cell carcinoma</article-title><source>Cancer Metastasis Rev</source><year>2021</year><volume>41</volume><issue>1</issue><fpage>17</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">34741716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10555-021-09996-w</pub-id><pub-id pub-id-type="pmcid">PMC10045462</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Heravi G, Yazdanpanah O, Podgorski I, Matherly LH, Liu W. Lipid metabolism reprogramming in renal cell carcinoma. Cancer Metastasis Rev. 2021;41(1):17&#8211;31.<pub-id pub-id-type="pmid">34741716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10555-021-09996-w</pub-id><pub-id pub-id-type="pmcid">PMC10045462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>I</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>VS</given-names></name><name name-style="western"><surname>Tan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Isom</surname><given-names>DG</given-names></name><name name-style="western"><surname>Lombard</surname><given-names>DB</given-names></name><etal/></person-group><article-title>GPR1 and CMKLR1 control lipid metabolism to support the development of clear cell renal cell carcinoma</article-title><source>Cancer Res</source><year>2024</year><volume>84</volume><issue>13</issue><fpage>2141</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">38640229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-23-2926</pub-id><pub-id pub-id-type="pmcid">PMC11290988</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Wang D, Mahmud I, Thakur VS, Tan SK, Isom DG, Lombard DB, et al. GPR1 and CMKLR1 control lipid metabolism to support the development of clear cell renal cell carcinoma. Cancer Res. 2024;84(13):2141&#8211;54.<pub-id pub-id-type="pmid">38640229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-23-2926</pub-id><pub-id pub-id-type="pmcid">PMC11290988</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Klasson TD, LaGory EL, Zhao H, Huynh SK, Papandreou I, Moon EJ et al. ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma. Cancer Metabolism. 2022;10(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40170-022-00290-z</pub-id><pub-id pub-id-type="pmcid">PMC9528056</pub-id><pub-id pub-id-type="pmid">36192773</pub-id></mixed-citation></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Blood lipid metabolic profiles and causal links to Site-Specific cancer risks: A Mendelian randomization study</article-title><source>Nutr Cancer</source><year>2024</year><volume>76</volume><issue>2</issue><fpage>175</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">38166549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01635581.2023.2294521</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Chen K, Li J, Ouyang Y, Liu G, Xie Y, Xu G, et al. Blood lipid metabolic profiles and causal links to Site-Specific cancer risks: A Mendelian randomization study. Nutr Cancer. 2024;76(2):175&#8211;86.<pub-id pub-id-type="pmid">38166549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01635581.2023.2294521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navas</surname><given-names>LE</given-names></name><name name-style="western"><surname>Carnero</surname><given-names>A</given-names></name></person-group><article-title>NAD&#8201;+&#8201;metabolism, stemness, the immune response, and cancer</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>2</fpage><pub-id pub-id-type="pmid">33384409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00354-w</pub-id><pub-id pub-id-type="pmcid">PMC7775471</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Navas LE, Carnero A. NAD&#8201;+&#8201;metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021;6(1):2.<pub-id pub-id-type="pmid">33384409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00354-w</pub-id><pub-id pub-id-type="pmcid">PMC7775471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>CD25: A potential tumor therapeutic target</article-title><source>Int J Cancer</source><year>2023</year><volume>152</volume><issue>7</issue><fpage>1290</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">36082452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.34281</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Peng Y, Tao Y, Zhang Y, Wang J, Yang J, Wang Y. CD25: A potential tumor therapeutic target. Int J Cancer. 2023;152(7):1290&#8211;303.<pub-id pub-id-type="pmid">36082452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.34281</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whisenant</surname><given-names>TC</given-names></name><name name-style="western"><surname>Nigam</surname><given-names>SK</given-names></name></person-group><article-title>Organic anion transporters (OAT) and other SLC22 transporters in progression of renal cell carcinoma</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><fpage>19</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14194772</pub-id><pub-id pub-id-type="pmcid">PMC9563088</pub-id><pub-id pub-id-type="pmid">36230695</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Whisenant TC, Nigam SK. Organic anion transporters (OAT) and other SLC22 transporters in progression of renal cell carcinoma. Cancers (Basel). 2022;14:19.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14194772</pub-id><pub-id pub-id-type="pmcid">PMC9563088</pub-id><pub-id pub-id-type="pmid">36230695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tipton</surname><given-names>AR</given-names></name><name name-style="western"><surname>Wren</surname><given-names>JD</given-names></name><name name-style="western"><surname>Daum</surname><given-names>JR</given-names></name><name name-style="western"><surname>Siefert</surname><given-names>JC</given-names></name><name name-style="western"><surname>Gorbsky</surname><given-names>GJ</given-names></name></person-group><article-title>GTSE1 regulates spindle microtubule dynamics to control Aurora B kinase and Kif4A chromokinesin on chromosome arms</article-title><source>J Cell Biol</source><year>2017</year><volume>216</volume><issue>10</issue><fpage>3117</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">28821562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201610012</pub-id><pub-id pub-id-type="pmcid">PMC5626529</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Tipton AR, Wren JD, Daum JR, Siefert JC, Gorbsky GJ. GTSE1 regulates spindle microtubule dynamics to control Aurora B kinase and Kif4A chromokinesin on chromosome arms. J Cell Biol. 2017;216(10):3117&#8211;32.<pub-id pub-id-type="pmid">28821562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201610012</pub-id><pub-id pub-id-type="pmcid">PMC5626529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>GTSE1 promotes tumor growth and metastasis by attenuating of KLF4 expression in clear cell renal cell carcinoma</article-title><source>Lab Invest</source><year>2022</year><volume>102</volume><issue>9</issue><fpage>1011</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">35585131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41374-022-00797-5</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Chen W, Wang H, Lu Y, Huang Y, Xuan Y, Li X, et al. GTSE1 promotes tumor growth and metastasis by attenuating of KLF4 expression in clear cell renal cell carcinoma. Lab Invest. 2022;102(9):1011&#8211;22.<pub-id pub-id-type="pmid">35585131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41374-022-00797-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in CcRCC and is associated with immune infiltrates and poor prognosis</article-title><source>Front Genet</source><year>2023</year><volume>14</volume><fpage>996362</fpage><pub-id pub-id-type="pmid">36999057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2023.996362</pub-id><pub-id pub-id-type="pmcid">PMC10043236</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Lei P, Zhang M, Li Y, Wang Z. High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in CcRCC and is associated with immune infiltrates and poor prognosis. Front Genet. 2023;14:996362.<pub-id pub-id-type="pmid">36999057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2023.996362</pub-id><pub-id pub-id-type="pmcid">PMC10043236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capelluto</surname><given-names>DG</given-names></name></person-group><article-title>Tollip: a multitasking protein in innate immunity and protein trafficking</article-title><source>Microbes Infect</source><year>2012</year><volume>14</volume><issue>2</issue><fpage>140</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21930231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2011.08.018</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Capelluto DG. Tollip: a multitasking protein in innate immunity and protein trafficking. Microbes Infect. 2012;14(2):140&#8211;7.<pub-id pub-id-type="pmid">21930231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2011.08.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pimentel-Nunes</surname><given-names>P</given-names></name><name name-style="western"><surname>Goncalves</surname><given-names>N</given-names></name><name name-style="western"><surname>Boal-Carvalho</surname><given-names>I</given-names></name><name name-style="western"><surname>Afonso</surname><given-names>L</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>P</given-names></name><name name-style="western"><surname>Roncon-Albuquerque</surname><given-names>R</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Helicobacter pylori induces increased expression of Toll-like receptors and decreased Toll-interacting protein in gastric mucosa that persists throughout gastric carcinogenesis</article-title><source>Helicobacter</source><year>2013</year><volume>18</volume><issue>1</issue><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">23061653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/hel.12008</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-Albuquerque R Jr., et al. Helicobacter pylori induces increased expression of Toll-like receptors and decreased Toll-interacting protein in gastric mucosa that persists throughout gastric carcinogenesis. Helicobacter. 2013;18(1):22&#8211;32.<pub-id pub-id-type="pmid">23061653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/hel.12008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Begka</surname><given-names>C</given-names></name><name name-style="western"><surname>Pattaroni</surname><given-names>C</given-names></name><name name-style="western"><surname>Mooser</surname><given-names>C</given-names></name><name name-style="western"><surname>Nancey</surname><given-names>S</given-names></name><name name-style="western"><surname>Swiss</surname><given-names>IBDCSG</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>KD</given-names></name><etal/></person-group><article-title>Toll-Interacting protein regulates immune cell infiltration and promotes Colitis-Associated cancer</article-title><source>iScience</source><year>2020</year><volume>23</volume><issue>3</issue><fpage>100891</fpage><pub-id pub-id-type="pmid">32114379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2020.100891</pub-id><pub-id pub-id-type="pmcid">PMC7049660</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Begka C, Pattaroni C, Mooser C, Nancey S, Swiss IBDCSG, McCoy KD, et al. Toll-Interacting protein regulates immune cell infiltration and promotes Colitis-Associated cancer. iScience. 2020;23(3):100891.<pub-id pub-id-type="pmid">32114379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2020.100891</pub-id><pub-id pub-id-type="pmcid">PMC7049660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><mixed-citation publication-type="other">Kowalewski A, Jaworski D, Borowczak J, Maniewski M, Szczerbowski K, Antosik P et al. TOLLIP protein expression predicts unfavorable outcome in renal cell carcinoma. Int J Mol Sci. 2022;23(23).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232314702</pub-id><pub-id pub-id-type="pmcid">PMC9741407</pub-id><pub-id pub-id-type="pmid">36499030</pub-id></mixed-citation></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoch</surname><given-names>A</given-names></name><name name-style="western"><surname>Auchynnikava</surname><given-names>T</given-names></name><name name-style="western"><surname>Berrens</surname><given-names>RV</given-names></name><name name-style="western"><surname>Kabayama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schopp</surname><given-names>T</given-names></name><name name-style="western"><surname>Heep</surname><given-names>M</given-names></name><etal/></person-group><article-title>SPOCD1 is an essential executor of piRNA-directed de Novo DNA methylation</article-title><source>Nature</source><year>2020</year><volume>584</volume><issue>7822</issue><fpage>635</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">32674113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2557-5</pub-id><pub-id pub-id-type="pmcid">PMC7612247</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Zoch A, Auchynnikava T, Berrens RV, Kabayama Y, Schopp T, Heep M, et al. SPOCD1 is an essential executor of piRNA-directed de Novo DNA methylation. Nature. 2020;584(7822):635&#8211;9.<pub-id pub-id-type="pmid">32674113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2557-5</pub-id><pub-id pub-id-type="pmcid">PMC7612247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">Gan L, Yang C, Zhao L, Wang S, Gao Z, Ye Y. Prognostic biomarker SPOCD1 and its correlation with immune infiltrates in colorectal cancer. Biomolecules. 2023;13(2).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom13020209</pub-id><pub-id pub-id-type="pmcid">PMC9953389</pub-id><pub-id pub-id-type="pmid">36830578</pub-id></mixed-citation></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y-Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X-L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H-M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q-D</given-names></name><etal/></person-group><article-title>SPOCD1 promotes the proliferation and metastasis of glioma cells by up-regulating PTX3</article-title><source>Am J Cancer Res</source><year>2018</year><volume>8</volume><issue>4</issue><fpage>624</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">29736308</pub-id><pub-id pub-id-type="pmcid">PMC5934553</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Liu Q, Wang X-Y, Qin Y-Y, Yan X-L, Chen H-M, Huang Q-D, et al. SPOCD1 promotes the proliferation and metastasis of glioma cells by up-regulating PTX3. Am J Cancer Res. 2018;8(4):624&#8211;35.<pub-id pub-id-type="pmid">29736308</pub-id><pub-id pub-id-type="pmcid">PMC5934553</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St-Pierre</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Loffree</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Considering strategies for SNP selection in genetic and polygenic risk scores</article-title><source>Front Genet</source><year>2022</year><volume>13</volume><fpage>900595</fpage><pub-id pub-id-type="pmid">36819922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.900595</pub-id><pub-id pub-id-type="pmcid">PMC9930898</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">St-Pierre J, Zhang X, Lu T, Jiang L, Loffree X, Wang L, et al. Considering strategies for SNP selection in genetic and polygenic risk scores. Front Genet. 2022;13:900595.<pub-id pub-id-type="pmid">36819922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.900595</pub-id><pub-id pub-id-type="pmcid">PMC9930898</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>